Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gynecology

  Free Subscription

Articles published in
Gynecol Oncol
    November 2026
  1. YOUSIF A, Elchouemi M, Asad AB
    Glucagon-like peptide-1 receptor agonist use and overall survival in endometrial cancer: a multicenter propensity score-matched cohort study.
    Gynecol Oncol. 2026;215:217-225.
    >> Share

  2. WANG Y, Kong Y, Che Y, Luan X, et al
    First-cycle beta-hCG dynamics predict single-agent chemoresistance in low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2026;215:209-216.
    >> Share

  3. AREND RC, Dave D, Cosgrove CM, Kohn E, et al
    Translational science in modern gynecologic oncology trials.
    Gynecol Oncol. 2026;215:180-191.
    >> Share

  4. DUNLAP CE, Meade CE, Sinnott JA, Lozano-Esparza S, et al
    Racial and ethnic differences in ovarian cancer survival across SEER registry states.
    Gynecol Oncol. 2026;215:168-179.
    >> Share

  5. HURTEAU J, Grayeski M, Dixon J
    BEHOLD phase 3 clinical development program of mocertatug rezetecan in ovarian and endometrial cancer.
    Gynecol Oncol. 2026;215:164-167.
    >> Share

  6. YEN TT, Hsieh TYJ, Lee GY, Melamed A, et al
    Time to treatment initiation in cervical cancer in the United States: Trends by treatment modality and factors associated with delay.
    Gynecol Oncol. 2026;215:154-163.
    >> Share

  7. ZITTER R, Sivananthan AP, Son CH, Hasan Y, et al
    National cancer database analysis of uterine carcinosarcoma: An updated series in locally advanced stage patients.
    Gynecol Oncol. 2026;215:146-153.
    >> Share

  8. MELAMED A, Covens AL, Pfaendler KS, Nakayama J, et al
    Surgical management of cervical cancer: A Society of Gynecologic Oncology evidence-based review.
    Gynecol Oncol. 2026;215:124-132.
    >> Share

  9. CORTEZ CA, Taffe BD, Ellis C, Albright BB, et al
    Barriers to treatment for patients diagnosed with cervical cancer: A systematic review.
    Gynecol Oncol. 2026;215:136-145.
    >> Share

  10. LLUECA A
    Beyond the surgeon's eye: towards a molecular definition of complete cytoreduction in advanced ovarian cancer.
    Gynecol Oncol. 2026;215:133-135.
    >> Share

  11. SHAO H, Zhao Y, Cui T, Wang T, et al
    Prophylactic extended-field irradiation versus pelvic radiotherapy in high-risk locally advanced cervical cancer with radiologically negative para-aortic lymph nodes: a retrospective cohort study.
    Gynecol Oncol. 2026;215:116-123.
    >> Share

  12. WARRING SK, Peng KW, Atherton PJ, Asmus EJ, et al
    A phase I trial of intravenous vesicular stomatitis virus expressing thyroidal sodium iodide symporter (NIS) and human interferon beta (hIFNbeta) in metastatic or recurrent endometrial cancer.
    Gynecol Oncol. 2026;215:94-102.
    >> Share

  13. DOHERTY ME, Malik M, Otsuka Y, Ellery H, et al
    Novel orthotopic uterine leiomyosarcoma model demonstrated enhanced tumor growth, metastasis, and chemosensitivity compared to subcutaneous counterparts.
    Gynecol Oncol. 2026;215:103-115.
    >> Share

  14. CHEN J, Zhu G, Sun Y, Yu H, et al
    De-escalation strategies and fertility preservation in Stage I placental site trophoblastic tumor: an individual patient data systematic review and institutional series.
    Gynecol Oncol. 2026;215:85-93.
    >> Share

  15. STROEKEN Y, van den Berg MC, Zusterzeel PLM, Zweemer RP, et al
    Fertility and pregnancy concerns and needs after fertility-sparing surgery in young women with gynecological cancer and their partners: A qualitative study.
    Gynecol Oncol. 2026;215:64-70.
    >> Share

    October 2026
  16. CHANG HH, Hsieh TYJ, Esselen KM, Hacker MR, et al
    Trends in use of glucagon-like peptide-1 receptor agonists in obese patients with endometrial cancer.
    Gynecol Oncol. 2026;215:58-63.
    >> Share

  17. FAROLFI A, Casadei C, Strada I, Petracci E, et al
    Human papillomavirus vaccination following cervical intraepithelial neoplasia and subsequent cervical cancer: A retrospective propensity score-matched cohort study.
    Gynecol Oncol. 2026;215:52-57.
    >> Share

  18. ONISHI J, Nagamine M, Wakabayashi M, Ohara J, et al
    Thoracic recurrence after complete gross resection in advanced ovarian cancer: The clinical impact of occult subdiaphragmatic lymphatic invasion.
    Gynecol Oncol. 2026;215:42-51.
    >> Share

  19. BARBER EL, Paraghamian S, Taylor J, Riedinger C, et al
    Defining quality care in gynecologic cancers: A Society of Gynecologic Oncology review.
    Gynecol Oncol. 2026;215:32-40.
    >> Share

  20. RIESE C, Yi-Tung Chen E, Nilsson H, Salehi S, et al
    Corrigendum to "Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old)". [Gynecol. Oncol. 212 (2026) 152-159].
    Gynecol Oncol. 2026;215:41.
    >> Share

  21. SCHILDKRAUT JM, Marks JR, Peres LC, Song X, et al
    The Duffy-Null genotype and epithelial ovarian cancer survival in a cohort of Black women.
    Gynecol Oncol. 2026;215:16-24.
    >> Share

  22. LI F, Li D, Xi Y, Wang W, et al
    Heterogeneity of folate receptor alpha expression and associations with molecular biomarker in ovarian high-grade serous carcinoma: A multicenter Chinese cohort study.
    Gynecol Oncol. 2026;214:182-189.
    >> Share

  23. DAVIDSON B, Holth A, Horni Gloersen G
    LMOD1 expression and survival in uterine leiomyosarcoma: discordant results in tissue microarrays and whole sections.
    Gynecol Oncol. 2026;215:7-15.
    >> Share

  24. HOLT HK, Ma W, Gordon HS, Sun J, et al
    Trends in utilization of cervical cancer screening and screening-associated services in a multi-organizational research network in Chicago, Illinois, US.
    Gynecol Oncol. 2026;214:173-181.
    >> Share

  25. COQUAN E, Vion R, Colomba-Blamemble E, Frenel JS, et al
    Phase II study of cabozantinib in recurrent or metastatic cervical cancer after progression on platinum-based chemotherapy (CABOCOL).
    Gynecol Oncol. 2026;214:164-172.
    >> Share

  26. ABDEEN CS, Sciuva J, O'Connor RM, Fulton J, et al
    Incidence and clinical impact of venous thromboembolism during immunotherapy for gynecologic cancer.
    Gynecol Oncol. 2026;215:1-6.
    >> Share

  27. GRISHAM RN, Slomovitz B, Podder V, Sun C, et al
    Low-grade serous ovarian cancer: 2026 expert consensus report.
    Gynecol Oncol. 2026;214:144-163.
    >> Share

  28. THORNTON S, O'Loughlin M, Nuk J, Borle K, et al
    A cross-sectional survey exploring experiences in accessing hormone replacement therapy following risk-reducing surgery for individuals with hereditary ovarian cancer risk.
    Gynecol Oncol. 2026;214:135-143.
    >> Share

  29. EVANS E, Dholakia J, Abraham J, Hinton A, et al
    Corrigendum to "Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors" [Gynecol. Oncol. 197 (2025) 139-145].
    Gynecol Oncol. 2026;214:134.
    >> Share

  30. VELASQUEZ J, Chalif J, Glassman D, Gonzalez A, et al
    How slow should we go? Variation and outcomes of steroid tapering for immunotherapy-related toxicities in gynecologic cancer.
    Gynecol Oncol. 2026;214:128-133.
    >> Share

  31. AGUSTI N, Bercow A, Ramirez PT, Plante M, et al
    Implementation and sustainability of surgical randomized trials in gynecologic oncology: Adoption beyond publication.
    Gynecol Oncol. 2026;214:119-127.
    >> Share

  32. BETELLA I, Bonetti E, Ribero L, Zanzottera C, et al
    Clinical implications of germline and somatic genetic testing in ovarian carcinoma: BRCA and beyond. The PERSONA-Ovary trial.
    Gynecol Oncol. 2026;214:110-118.
    >> Share

  33. ASSAVAPOKEE N, Gellman C, Blank SV, Carr C, et al
    Trends in immunotherapy utilization among older adults with advanced endometrial cancer: An NCDB analysis.
    Gynecol Oncol. 2026;214:102-109.
    >> Share

  34. SALOMON C, Lai A, Guanzon D, Scholz-Romero K, et al
    Immunoaffinity-enriched extracellular vesicle proteomics for high-grade serous ovarian cancer - A UKOPS nested case-control analysis.
    Gynecol Oncol. 2026;214:94-101.
    >> Share

  35. LEE S, So KA, Kim S, Lee MK, et al
    Genomic characterization of advanced and recurrent endometrial carcinoma: KRAS and TP53 co-mutation as a biomarker for adverse prognosis and therapeutic failure.
    Gynecol Oncol. 2026;214:83-93.
    >> Share

  36. GRAVES SM, Yoh K, Sia TY, Makker V, et al
    Impact of adjuvant treatment on survival in surgically staged 2009 FIGO stage I uterine serous carcinoma.
    Gynecol Oncol. 2026;214:75-82.
    >> Share

  37. MITSUHASHI A, Yamagami W, Inaba Y, Mikami Y, et al
    Effects of adjunctive metformin on recurrence-free survival and reproductive outcomes following progestin-based fertility-sparing treatment for endometrial neoplasia: Results from the FELICIA trial, a prospective, randomized, phase IIb trial with blin
    Gynecol Oncol. 2026;214:66-74.
    >> Share

  38. CHALIF J, Morton M, O'Connor R, Gonzalez A, et al
    A second chance? Outcomes of immunotherapy retreatment after prior checkpoint inhibitor exposure in endometrial and cervical cancer.
    Gynecol Oncol. 2026;214:59-65.
    >> Share

  39. MCCLAIN KM, Prabhu VS, Marupuru S, Meng K, et al
    Real-world outcomes of first-line pembrolizumab monotherapy among dMMR/MSI-H advanced or recurrent endometrial cancer patients in the United States.
    Gynecol Oncol. 2026 Oct 9:S0090-8258(26)02101.
    >> Share

  40. TEWARI KS
    Platinum resistant ovarian cancer - No longer a graveyard for drug development.
    Gynecol Oncol. 2026;214:34-42.
    >> Share

  41. IACOBELLI V, Romano V, Anderson G, Dababou S, et al
    Molecular biomarkers in uterine sarcomas: a review of reviews with genomic data integration.
    Gynecol Oncol. 2026;214:43-58.
    >> Share

  42. SUH-BURGMANN E, Finertie H, Hung YY, Hoodfar E, et al
    Prevalence of pathogenic germline variants and indications for testing in a diverse community-based endometrial cancer cohort.
    Gynecol Oncol. 2026;214:27-33.
    >> Share

  43. SMITH G, Petty A, Krivanek K, Rose PG, et al
    Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer.
    Gynecol Oncol. 2026;214:22-26.
    >> Share

  44. WENHAM RM, Ray-Coquard I, Kristeleit R, Matei D, et al
    Farletuzumab ecteribulin, a folate receptor alpha (FRalpha) antibody-drug conjugate, in select advanced cancers: An open-label, multicenter, phase 1/2 dose-finding study.
    Gynecol Oncol. 2026;213:109-119.
    >> Share

  45. FRODING LP, Christensen A, Kristensen E, Mortensen J, et al
    Feasibility of real-time near-infrared fluorescence tracer imaging in sentinel lymph node biopsy for vulvar cancer patients.
    Gynecol Oncol. 2026;213:89-94.
    >> Share

  46. MORSKY MK, Purolainen S, Kaartinen IS, Mattila VM, et al
    Contemporary surgical management of vulvar cancer is associated with improved survival but increased reoperation rate: A Finnish nationwide study.
    Gynecol Oncol. 2026;213:72-81.
    >> Share

  47. GERSHENSON DM
    MEK-Ing progress in low-grade serous ovarian cancer.
    Gynecol Oncol. 2026;213:A1-A3.
    >> Share

    September 2026
  48. DURMUS AB, Yucel GS
    The diagnostic value of serum glucagon-like peptide-1 (GLP-1) levels in endometrial cancer among obese women.
    Gynecol Oncol. 2026;213:102-108.
    >> Share

  49. SALINARO JR, Marketkar S, Haddock P, James N, et al
    Concordance between gastric HER2 scores for endometrial sampling versus hysterectomy specimens in endometrial cancer.
    Gynecol Oncol. 2026;214:1-6.
    >> Share

  50. O'CONNOR RM, Sinnott JA, Meade CE, Kanal SA, et al
    Association of community-level social vulnerability with county-level clinical trial access among ovarian cancer patients.
    Gynecol Oncol. 2026;213:95-101.
    >> Share

  51. GONZALEZ A, Chalif J, O'Connor R, McLaughlin E, et al
    Immunotherapy-induced thyroid dysfunction and diabetes mellitus in gynecologic oncology patients: a retrospective cohort study.
    Gynecol Oncol. 2026;214:7-14.
    >> Share

  52. MAH SJ, Seow H, Carter Ramirez DM, Eiriksson LR, et al
    Impact of palliative radiotherapy in patients with gynecologic malignancies on end-of-life outcomes.
    Gynecol Oncol. 2026;213:82-88.
    >> Share

  53. EDWARDS CC, Turner KA, Dinkins KG, Ketch PW, et al
    A phase II study in newly diagnosed stage III/IV epithelial ovarian cancer evaluating carboplatin/taxol/pembrolizumab in patients receiving neoadjuvant chemotherapy followed by pembrolizumab maintenance with or without olaparib.
    Gynecol Oncol. 2026;213:68-71.
    >> Share

  54. GRISHAM RN, Van Nieuwenhuysen E, Santin AD, D'Hondt V, et al
    Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
    Gynecol Oncol. 2026;213:59-67.
    >> Share

  55. WARRING SK, Knyazhanskaya EE, Garda AE, Cliby WA, et al
    Prognostic implications of HPV and TP53 status in early-stage vulvar squamous cell carcinoma.
    Gynecol Oncol. 2026;213:50-58.
    >> Share

  56. BERCOW AS, Agusti N, Ramirez P, Knisley A, et al
    Planning and feasibility of phase III surgical trials in gynecologic oncology.
    Gynecol Oncol. 2026;213:7-14.
    >> Share

  57. DENG L, Zheng Y, Yang F, Wang Q, et al
    Minimally invasive surgery without a uterine manipulator versus open radical hysterectomy for early-stage cervical cancer: A retrospective propensity-score-matched single-center cohort study.
    Gynecol Oncol. 2026;213:41-49.
    >> Share

  58. WELP AM, Mabry AR, Lines CL, Thaker PH, et al
    Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer.
    Gynecol Oncol. 2026;213:33-40.
    >> Share

  59. RAFFONE A, Neola D, Tranchini A, Mele M, et al
    Molecular groups predict response to fertility-sparing treatment of endometrial carcinoma: a systematic review and metanalysis.
    Gynecol Oncol. 2026;213:25-32.
    >> Share

  60. SILK T, Matulonis UA, Konstantinopoulos PA
    Molecular characterization of NSMP endometrial cancer and its relevance for treatment.
    Gynecol Oncol. 2026;213:15-24.
    >> Share

  61. SAKACH JC, Morton M, Velasquez JM, O'Connor RM, et al
    No time to waste: Evaluation of diagnostic delays in vulvar cancer.
    Gynecol Oncol. 2026;212:43-49.
    >> Share

  62. FROEDING LP, Greimel E, Nordin A, Vistad I, et al
    Phase 1-3 cross-cultural development and pre-testing of the European Organisation of Research and Treatment of Cancer Vulva cancer questionnaire module (EORTC QLQ- VU).
    Gynecol Oncol. 2026;212:17-23.
    >> Share

  63. TEN EIKELDER M, Veldmate G, Pettai F, Schepens-Franke A, et al
    Clitoral reconstructive surgery for patients with vulvar carcinoma.
    Gynecol Oncol. 2026;212:1-8.
    >> Share

  64. SANDERS B, Walsh CS
    Pregnancy complications in gynecologic oncologists - A call to action to do better.
    Gynecol Oncol. 2026;212:A1-A2.
    >> Share

    August 2026
  65. THAYER EG, Roecker ZA, Roof KA, Gold HB, et al
    High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.
    Gynecol Oncol. 2026;213:1-6.
    >> Share

  66. CHAPMAN GC, Fedorenko O, Sheyn D, Reid A, et al
    Leveraging artificial intelligence in the early detection of ovarian cancer: Development and validation of a risk prediction model.
    Gynecol Oncol. 2026;212:199-206.
    >> Share

  67. AGUSTI N, Bercow A, Knisely A, Obermair A, et al
    The science and conduct of surgical trials in gynecologic oncology: A practical framework.
    Gynecol Oncol. 2026;212:188-198.
    >> Share

  68. RICHARDSON MT, Barry D, Steinberg JR, Holder K, et al
    Early-phase vs. late-phase clinical trials in gynecologic oncology: Trends in trial completion, reporting, and enrollment of racial and ethnic minority groups.
    Gynecol Oncol. 2026;212:181-187.
    >> Share

  69. WESTIN SN, Belotte J, Felicetti B, Aghera V, et al
    Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial.
    Gynecol Oncol. 2026;212:173-180.
    >> Share

  70. KO EM, Pae C, Mulugeta-Gordon L, Uwawaike D, et al
    Evaluating a patient ambassador program to improve clinical trial knowledge and intent to discuss gynecologic oncology trials.
    Gynecol Oncol. 2026;212:160-172.
    >> Share

  71. RIESE C, Yi-Tung E, Nilsson H, Salehi S, et al
    Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980-2023) with focus on younger women (0-49 years old).
    Gynecol Oncol. 2026;212:152-159.
    >> Share

  72. AINIO C, Caruso G, Alessi S, Aiello AA, et al
    Predicting residual disease and extent of surgery after neoadjuvant chemotherapy for ovarian cancer: Does the MSKCC model from the primary setting apply?
    Gynecol Oncol. 2026;212:145-151.
    >> Share

  73. NGUYEN AQ, Bednarek N, Al-Sawalha I, Nagele B, et al
    Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers.
    Gynecol Oncol. 2026;212:134-144.
    >> Share

  74. HARRINGTON S, El Ghazal N, Tung C, Husain F, et al
    The role of metabolic and bariatric surgery for obesity management in endometrial intraepithelial neoplasia and endometrial cancer: A Society of Gynecologic Oncology and Society of American Gastrointestinal and Endoscopic Surgeons clinical practice st
    Gynecol Oncol. 2026;212:31-42.
    >> Share

  75. SEO JH, Lee Y, Lim S, Chung YE, et al
    Dynamics of HER2 status in recurrent cervical cancer: Highlighting the clinical value of reassessment.
    Gynecol Oncol. 2026;212:125-133.
    >> Share

  76. ALEVATO R, Braga A, Paiva G, Junior EA, et al
    Persistent low-level real human chorionic gonadotropin after gestational trophoblastic disease: Natural history and predictors of subsequent gestational trophoblastic neoplasia.
    Gynecol Oncol. 2026;212:116-124.
    >> Share

  77. HOPP EE, Enserro D, Campos S, Chitiyo V, et al
    A phase II study of androgen receptor inhibition by darolutamide in combination with leuprolide acetate and exemestane in recurrent adult-type ovarian granulosa cell tumor.
    Gynecol Oncol. 2026;212:98-105.
    >> Share

  78. KOCIAN R, Koehler C, Di Martino G, Klat J, et al
    Quality of life outcomes after sentinel lymph node biopsy in patients with early-stage cervical cancer: Results from the prospective multicentre SENTIX study.
    Gynecol Oncol. 2026;212:106-115.
    >> Share

  79. OXLEY S, Dibden A, Whenham T, Wei X, et al
    Health-related quality of life after risk-reducing hysterectomy: a randomised vignette study.
    Gynecol Oncol. 2026;212:89-97.
    >> Share

  80. LANGE P, Kanal SA, Vidwans Y, Donneyong M, et al
    Factors associated with non-completion of gynecological cancer clinical trials.
    Gynecol Oncol. 2026;212:80-88.
    >> Share

  81. DE TOMMASI O, Palmieri L, Bellone S, Buza N, et al
    Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRalpha), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic sub
    Gynecol Oncol. 2026;212:72-79.
    >> Share

  82. WANG CC, Kildee I, Reasner E, Bednorski I, et al
    Feasibility, adherence, and patient experiences in a pilot randomized trial of home-based cognitive training intervention for gynecologic cancer-related cognitive impairment.
    Gynecol Oncol. 2026;212:64-71.
    >> Share

  83. HELPMAN L, Josephy D, Toderis L, Tkach V, et al
    Oral anticoagulants reduce venous thromboembolism rates in patients on 1st-line treatment for ovarian Cancer- A quality improvement project.
    Gynecol Oncol. 2026;212:57-63.
    >> Share

  84. AUBREY C, Svajger B, Batara J, Chapelsky S, et al
    The feasibility of a medically supervised preoperative weight loss program in patients with obesity and atypical hyperplasia, or low-grade endometrial carcinoma.
    Gynecol Oncol. 2026;212:50-56.
    >> Share

  85. CHESS I, Holtzman S, Cox M, Leschly J, et al
    "I was in the driver's seat": A qualitative analysis of factors promoting and delaying previvors' oophorectomy after risk-reducing salpingectomy.
    Gynecol Oncol. 2026;211:200-207.
    >> Share

  86. MARADIYA R, Kinloch M, De Leo A, de Biase D, et al
    The real-world utility of homologous repair deficiency testing in BRCA1/2 wild-type high-grade serous carcinoma and the utility of MYC amplification as a potential surrogate marker.
    Gynecol Oncol. 2026;211:148-152.
    >> Share

  87. JIANG A, Chen Y, Ma F, Zhang H, et al
    Malignant transformation risk and management dilemmas of atypical lobular endocervical glandular hyperplasia: A retrospective cohort study comparing Peutz-Jeghers syndrome versus sporadic cases.
    Gynecol Oncol. 2026;211:51-58.
    >> Share

  88. MAIORANO MFP, Cormio G, De Serio I, Torzillo FP, et al
    Occult invasive and preneoplastic lesions at risk-reducing salpingo-oophorectomy in BRCA1/2 carriers: A multicenter retrospective cohort study.
    Gynecol Oncol. 2026;211:29-36.
    >> Share

  89. MCALPINE JN, Mutch D
    A path to precision in endometrial cancer management: Moving past FIGO 2023.
    Gynecol Oncol. 2026;211:A1-A2.
    >> Share

    July 2026
  90. GOON KC, Chor J, Mills KA
    Pregnancies in gynecologic oncologists: An assessment of pregnancy policies and complications within a surgical subspecialty.
    Gynecol Oncol. 2026;212:24-30.
    >> Share

  91. BOITANO TKL, Bansal A, Dinkins KG, Fennell V, et al
    Understanding and addressing enrollment gaps and opportunities in gynecologic oncology clinical trials: A scoping review.
    Gynecol Oncol. 2026;212:9-16.
    >> Share

  92. FARABEE EA, Ahrendt HD, Lin M, Uczkowski NG, et al
    Failure to rescue after major gynecologic cancer surgery: A National Surgical Quality Improvement Program analysis.
    Gynecol Oncol. 2026;211:246-253.
    >> Share

  93. NOGUERAS GONZALEZ GM, Amboree TL, Parker S, Bulsara S, et al
    Barriers to cervical cancer screening and experiences using mailed at-home HPV self-collection kits among US and foreign-born Hispanic women in a safety net health system.
    Gynecol Oncol. 2026;211:238-245.
    >> Share

  94. BORDEN LE, Cosgrove CM, Washington CR, Thomas SM, et al
    MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
    Gynecol Oncol. 2026;211:231-237.
    >> Share

  95. DUKES D, Yost C, Wang R, Diagne YF, et al
    Guideline-anchored retrieval-augmented generation outperforms baseline and literature-only configurations in gynecologic oncology decision support: A pre-integration benchmark.
    Gynecol Oncol. 2026;211:224-230.
    >> Share

  96. CATOZZO A, Garzon S, Renso M, Raspagliesi F, et al
    Clinical utility of sentinel lymph node biopsy in atypical endometrial hyperplasia: A multicenter cohort study.
    Gynecol Oncol. 2026;211:217-223.
    >> Share

  97. LEITE LF, da Conceicao LD, de Almeida LFC, de Albuquerque LZ, et al
    Ovarian cancer global trends and disparities across 204 countries and territories.
    Gynecol Oncol. 2026;211:208-216.
    >> Share

  98. OTTUM S, Sethi N, Bellone S, Demirkiran C, et al
    Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.
    Gynecol Oncol. 2026;211:191-199.
    >> Share

  99. O'CONNOR RM, Chalif J, Gonzalez A, Glassman DC, et al
    Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer.
    Gynecol Oncol. 2026;211:185-190.
    >> Share

  100. SEGUIN CL, Eckel A, Howard DH, Peters MLB, et al
    Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States.
    Gynecol Oncol. 2026;211:178-184.
    >> Share

  101. BARBER EL, Wei JJ, Strickland AL, Moroney JW, et al
    Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.
    Gynecol Oncol. 2026;211:171-177.
    >> Share

  102. ZHAO CL, Wang XP, Wei K, Ge YJ, et al
    Folate receptor alpha, TROP2 and HER2 in high-grade serous ovarian Cancer: Expression and clinicopathological correlations.
    Gynecol Oncol. 2026;211:162-170.
    >> Share

  103. JEONG S, Kim S, Ouh YT, Lee S, et al
    Validation of the 2025 ESGO/ESTRO/ESP postoperative risk stratification system in endometrial cancer: A same-cohort comparison with the 2020 molecular classification.
    Gynecol Oncol. 2026;211:153-161.
    >> Share

  104. ZIMMERMAN J, Dadgar N, Krivak TC, Crafton SM, et al
    Immune checkpoint inhibition in ovarian cancer: Reassessing its potential.
    Gynecol Oncol. 2026;211:138-141.
    >> Share

  105. DILLON BS, Hood O, Chanda S, Madill M, et al
    An analysis of the readability of Gynecologic Cancer patient education materials.
    Gynecol Oncol. 2026;211:142-147.
    >> Share

  106. HAIGHT PJ, Sakach JC, Chambers LM, Backes FJ, et al
    Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?
    Gynecol Oncol. 2026;211:132-137.
    >> Share

  107. RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
    Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study.
    Gynecol Oncol. 2026;211:125-131.
    >> Share

  108. RICH BS, Fishbein JS, Purcell LN, Murphy JT, et al
    Immature teratoma of the ovary in children and adolescents: A multi-institutional study of characteristics and management.
    Gynecol Oncol. 2026;211:115-124.
    >> Share

  109. CATENA U, Dinoi G, Masciullo V, D'Alessandris N, et al
    Fertility-sparing treatment in stage IA grade 2 endometrioid endometrial cancer: Outcomes of a standardized approach.
    Gynecol Oncol. 2026;211:108-114.
    >> Share

  110. ROLLER L, Zhou N, Atre I, Xiong N, et al
    Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.
    Gynecol Oncol. 2026;211:98-107.
    >> Share

  111. YEN TT, Lu CA, Hsieh TYJ, Lee GY, et al
    Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.
    Gynecol Oncol. 2026;211:89-97.
    >> Share

  112. SHAHIN MS, Lorusso D, Backes FJ, Barretina-Ginesta MP, et al
    Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
    Gynecol Oncol. 2026;211:79-88.
    >> Share

  113. HAZNEDAR T, Durante S, Lazzari R, Corrao G, et al
    Stereotactic body radiotherapy for oligorecurrent granulosa cell tumours.
    Gynecol Oncol. 2026;210:140-147.
    >> Share

  114. ABDEEN CS, O'Connor RM, Chalif J, Glassman DC, et al
    Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma.
    Gynecol Oncol. 2026;210:72-76.
    >> Share

  115. LANGSTRAAT CL, Ostby SA, Vu A, Kalogera ES, et al
    Innovation through standardization: Reducing the ileostomy rates while targeting zero anastomotic leaks at cytoreductive surgery.
    Gynecol Oncol. 2026;210:49-54.
    >> Share

  116. LLOYD-ELLIS S, Kaur P, Kwon JS, Dawson L, et al
    Uptake of risk-reducing medical interventions among female BRCA1/2 pathogenic variant carriers: A population-based study in British Columbia.
    Gynecol Oncol. 2026;210:41-48.
    >> Share

  117. SMITS A, Dhanis J, Drager LD, de Hullu J, et al
    The impact of multimodal prehabilitation on surgical outcomes in gynaecological cancer surgery.
    Gynecol Oncol. 2026;210:32-40.
    >> Share

  118. TROZZI R, Anderson G, Romano V, Iacobelli V, et al
    A review of reviews of the prevalence of molecular biomarkers in vulvar cancer and their implications for prognosis refinement and treatment strategies.
    Gynecol Oncol. 2026;210:20-31.
    >> Share

  119. URMAN RD, Ljungqvist O
    The evolving landscape of personalized perioperative care: A commentary on the 2026 ERAS(R) Gynecologic oncology guidelines.
    Gynecol Oncol. 2026;210:A1-A2.
    >> Share

    June 2026
  120. CHAMBERS LM, Spakowicz D, Chalif J, O'Connor R, et al
    PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.
    Gynecol Oncol. 2026;211:74-78.
    >> Share

  121. MONTASSIER T, Laas E, Hotton J, Berton-Rigaud D, et al
    Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.
    Gynecol Oncol. 2026;211:59-66.
    >> Share

  122. KOURI A, Menzies A, Stearns K, McGough C, et al
    A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.
    Gynecol Oncol. 2026;211:67-73.
    >> Share

  123. YARUNIN A, Qiu P, Li X, Lukashchuk N, et al
    Technical evaluation of commercially available homologous recombination deficiency assays using MyChoice CDx as reference in ovarian cancer.
    Gynecol Oncol. 2026;210:217-225.
    >> Share

  124. ROY A, Iacob S, Chaffin A, Cunningham M, et al
    FIGO 2023 staging may result in overtreatment of early-stage endometrial cancer.
    Gynecol Oncol. 2026;211:46-50.
    >> Share

  125. FENG P, Shi K, Zhao W, Zhang J, et al
    Diagnostic value of FAM19A4/SOX1/PAX1 methylation in non-16/18 high-risk HPV cervical lesions.
    Gynecol Oncol. 2026;211:37-45.
    >> Share

  126. SULEIMAN R, Mokshagundam S, Block MS, Wahner Hendrickson AE, et al
    Prehabilitation during neoadjuvant chemotherapy in advanced ovarian cancer is associated with improved surgical candidacy and chemotherapy outcomes.
    Gynecol Oncol. 2026;211:9-16.
    >> Share

  127. BERGERON AM, Kisiel M, Lavecchia M, Mah S, et al
    Could chemotherapy response score act as a surrogate marker of response to PARP inhibitor maintenance treatment in patients with advanced ovarian cancer?
    Gynecol Oncol. 2026;211:23-28.
    >> Share

  128. LEE J, Seo K, Kim J, Son JH, et al
    Corrigendum to "Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer" [Volume 208, May 2026, Pages 85-90].
    Gynecol Oncol. 2026;211:8.
    >> Share

  129. ALASHQAR A, Clark M, Gross CP, Spatz ES, et al
    Cardiovascular outcomes in individuals with ovarian cancer: A retrospective cohort study.
    Gynecol Oncol. 2026;211:17-22.
    >> Share

  130. MAH SJ, Bergeron AM, Hanley G, Yang I, et al
    Opportunistic salpingectomy during non-gynecologic surgery: Canadian surgeons' experience, barriers and facilitators.
    Gynecol Oncol. 2026;211:1-7.
    >> Share

  131. GAILLARD S, Parker J, Broadwater G, Duska L, et al
    Atezolizumab in combination with neoadjuvant chemotherapy and interval cytoreductive surgery for patients with newly diagnosed advanced-stage epithelial ovarian cancer: the AdORN study.
    Gynecol Oncol. 2026;210:208-216.
    >> Share

  132. DESRAVINES N, Tschudy MM, Hazimeh D, Brown K, et al
    Raising the bar on surgical site infection bundles: Preoperative penicillin allergy testing in gynecologic oncology patients with a reported penicillin allergy - A quality improvement study.
    Gynecol Oncol. 2026;210:200-207.
    >> Share

  133. LLANORA JD, Hayse C, Janke MJ, Liu Y, et al
    Referral patterns for genetic counseling and completion of germline testing in patients younger than 50 years with endometrial cancer.
    Gynecol Oncol. 2026;210:193-199.
    >> Share

  134. VALSTAD H, Fauske L, Wang YY, Eyjolfsdottir B, et al
    Pelvic exenteration for cervical cancer - Oncologic outcome and long-term health-related quality of life, a mixed methods study.
    Gynecol Oncol. 2026;210:183-192.
    >> Share

  135. TANG X, Huang H, Peipert JD, Zola A, et al
    Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004.
    Gynecol Oncol. 2026;210:174-182.
    >> Share

  136. NELSON G, Altman AD, Metcalfe A, Fotopoulou C, et al
    Enhanced recovery after surgery (ERAS(R)) society guidelines for gynecologic oncology: 2026 update.
    Gynecol Oncol. 2026;210:153-173.
    >> Share

  137. KONG TW, Lee J, Kim J, Son JH, et al
    A multicenter study of laparoscopic versus laparotomic surgery in the treatment of stage I adult granulosa cell and Sertoli-Leydig cell tumors: (LARGES): Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-3005).
    Gynecol Oncol. 2026;210:148-152.
    >> Share

  138. CARVALHO SN, Soldin I, Silva RM, Domingues TD, et al
    Clinical relevance of homologous recombination repair gene alterations in endometrial cancer patients in the era of molecular classification.
    Gynecol Oncol. 2026;210:124-130.
    >> Share

  139. LEE YJ, Park J, Kim YN, Kim S, et al
    Histology-specific ADC target landscapes in ovarian cancer and therapy-associated antigen downshift after ADC exposure.
    Gynecol Oncol. 2026;210:131-139.
    >> Share

  140. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
    Clinical relevance of transcriptome profiling for assessing prognosis, platinum insensitivity, and precision therapeutics in endometrial cancer.
    Gynecol Oncol. 2026;210:114-123.
    >> Share

  141. BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
    Corrigendum to 'Endometriosis and ovarian cancer risk' [Gynecologic Oncology 209C (2026) 88-98].
    Gynecol Oncol. 2026;210:113.
    >> Share

  142. PANDRAKLAKIS A, Shearer AM, Ellis LB, Oikonomou MD, et al
    Primary ovarian malignant melanoma: A systematic review of cases and pooled analysis.
    Gynecol Oncol. 2026;210:95-105.
    >> Share

  143. WOLSWINKEL JT, Bekkers AHPA, Maurits JSF, Bekkers RLM, et al
    Preoperative LVSI assessment in early-stage cervical cancer: Can it reliably guide lymph node management?
    Gynecol Oncol. 2026;210:106-112.
    >> Share

  144. KARLSEN NS, Hogdall CK, Dreisler E, Sakse AE, et al
    Adding HE4 to the IOTA ADNEX model for differentiating adnexal masses: A Danish prospective, multicenter study.
    Gynecol Oncol. 2026;209:111-119.
    >> Share

  145. ZHANG X, Shahryari J, Kingsley LG, McCluggage WG, et al
    Expression of the antibody-drug conjugate targets TROP2, CLDN6, B7-H3, and DLL3 in mesonephric-like adenocarcinoma of the female genital tract.
    Gynecol Oncol. 2026;209:62-68.
    >> Share

  146. SALANI R, Chase DM, Karlan BY
    En-Do's and En-Don'ts: Navigating the rapidly evolving clinical landscape in endometrial cancer.
    Gynecol Oncol. 2026;209:A1-A2.
    >> Share

    May 2026
  147. SOIFFER JL, Suresh D, Jalai C, Xu Y, et al
    Risk of endometrial carcinoma in patients with atypical endometrial hyperplasia in a population of predominantly racial and ethnic minorities, a single institution study.
    Gynecol Oncol. 2026;210:77-83.
    >> Share

  148. DIXIT R, Chakrawal A, Purwar R, Pandey M, et al
    Comparative performance of HPV self-sampling and conventional screening methods: A systematic review and bivariate meta-analysis.
    Gynecol Oncol. 2026;210:84-94.
    >> Share

  149. POWELL MA, Roed H, Willmott LJ, Cibula D, et al
    Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
    Gynecol Oncol. 2026 May 29:S0090-8258(26)01985.
    >> Share

  150. KUROKI LM, Enserro DM, Lankes HA, Strickland KC, et al
    Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
    Gynecol Oncol. 2026;210:63-71.
    >> Share

  151. SMICK AH, Zurek N, Taylor-Harding B, Karlan BY, et al
    Molecular and spatial differences in the tumor microenvironment of high-grade serous ovarian cancers with short versus long-term survival.
    Gynecol Oncol. 2026;210:55-62.
    >> Share

  152. BORCINOVA M, Knize M, Brtnicky T, Presl J, et al
    Multimodal prehabilitation in patients with advanced ovarian cancer.
    Gynecol Oncol. 2026;210:10-19.
    >> Share

  153. BRAND-WIITA S, Tsai CJ, Liu YH, Beaulieu E, et al
    Cost-effectiveness of pembrolizumab as a treatment for FIGO 2014 stage III-IVA cervical cancer in the United States.
    Gynecol Oncol. 2026;210:1-9.
    >> Share

  154. SARGAZI N, Afshari S, Nahvijou A, Daroudi R, et al
    Cost-effectiveness of Pembrolizumab in advanced endometrial cancer: A systematic review.
    Gynecol Oncol. 2026;209:146-157.
    >> Share

  155. JAMIESON A, Kwon J, Gao T, Lee J, et al
    Assessing the essential parameters of race, ethnicity and geography in endometrial cancer and the impact on presentation, treatment and outcomes.
    Gynecol Oncol. 2026;209:158-166.
    >> Share

  156. FINCH L, Dagher C, Harlev C, Finlan M, et al
    Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2026;209:138-145.
    >> Share

  157. CAO Y, Liu Q, Zhou H, Yu M, et al
    Longitudinal trajectories of anxiety and depression in patients with endometrial cancer or atypical endometrial hyperplasia undergoing fertility-sparing treatment.
    Gynecol Oncol. 2026;209:131-137.
    >> Share

  158. URBAN R, Eskander R, Westin S, Powell M, et al
    Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations, part II.
    Gynecol Oncol. 2026;209:120-130.
    >> Share

  159. TURNER KA, Edwards CC, Ketch PW, Dinkins KG, et al
    A phase Ib/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma.
    Gynecol Oncol. 2026;209:107-110.
    >> Share

  160. PHUNG MT, Barroilhet LM, Binkley N, Gangnon RE, et al
    Longitudinal dynamics of post-diagnosis frailty among older women with ovarian cancer.
    Gynecol Oncol. 2026;209:99-106.
    >> Share

  161. BOGANI G, Moore KN, Ray-Coquard I, Ceccaroni M, et al
    Endometriosis and ovarian cancer risk.
    Gynecol Oncol. 2026;209:88-98.
    >> Share

  162. SHACHAR E, Rotkop G, Haas R, Frankenthal R, et al
    Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy.
    Gynecol Oncol. 2026;209:77-87.
    >> Share

  163. GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
    Corrigendum to "Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery" [Gynecol Oncol. 2026 Apr;207:16
    Gynecol Oncol. 2026;209:75-76.
    >> Share

  164. LUKEY A, Salmanpour A, Kaur P, Berchuck A, et al
    Estrogen hormone therapy use in ovarian cancer patients under age 60 at diagnosis.
    Gynecol Oncol. 2026;209:69-74.
    >> Share

  165. WAGGONER RM, Ricker CN, Nie Q, Guo XM, et al
    Risk-reducing gynecologic surgery decisions in Lynch syndrome at a safety-net hospital and university medical center.
    Gynecol Oncol. 2026;209:56-61.
    >> Share

  166. GRUBE M, Ribeiro de Souza B, Neilson A, Tinker A, et al
    Lymph node involvement, surgery and adjuvant treatment in primary Endometrioid Ovarian carcinoma PAtients with eaRly-stage Disease (LEOPARD) - a multinational team initiative.
    Gynecol Oncol. 2026;209:48-55.
    >> Share

  167. LUDMIR D, Huang Y, Xu X, Dioun S, et al
    Impact of lymphadenectomy on survival outcomes for stage I malignant ovarian germ cell tumors.
    Gynecol Oncol. 2026;209:40-47.
    >> Share

  168. MUSA FB, Boyle TAC, Lim JT, Moore J, et al
    Real-world monitoring and clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study.
    Gynecol Oncol. 2026;209:33-39.
    >> Share

  169. BURNS R, Esposito A, Keomany J, Okut H, et al
    A comparison of vulvar surgery outcomes after prophylactic antibiotic use.
    Gynecol Oncol. 2026;208:100-105.
    >> Share

  170. NELSON OL, Rosales R, Turbov J, Thaete LG, et al
    Progestin and vitamin D synergistically inhibit fallopian tube carcinogenesis.
    Gynecol Oncol. 2026;208:8-16.
    >> Share

  171. SAULE C, Laas E, Weber N, Bataillon G, et al
    Peritoneal cancer risk after risk reducing salpingo-oophorectomy, impact of mutational status and STIC lesions.
    Gynecol Oncol. 2026;208:1-7.
    >> Share

  172. DAVIS JM, Dudley JC, Fader AN
    Tampon-based methylated DNA testing for endometrial cancer: Promising innovation, but prudence before practice.
    Gynecol Oncol. 2026;208:A1-A2.
    >> Share

    April 2026
  173. SHACHAR EK, Silverstein J, Kwan L, Salani R, et al
    Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?
    Gynecol Oncol. 2026;209:26-32.
    >> Share

  174. URBAN R, Castellano T, Doll K, DeLair D, et al
    Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I.
    Gynecol Oncol. 2026;209:15-25.
    >> Share

  175. CAGDAS EK
    Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses.
    Gynecol Oncol. 2026;209:7-14.
    >> Share

  176. SORRENTINO L, Bogani G, Chiappa V, Lalli L, et al
    Predictive features of anastomotic leakage after colorectal resection in complex multivisceral cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2026;209:1-6.
    >> Share

  177. OGASAWARA A, Suzuki S, Oda K, Yunokawa M, et al
    Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
    Gynecol Oncol. 2026;208:122-130.
    >> Share

  178. KIM JH, Hwang WY, Choi CH, Kim HS, et al
    Oncologic outcomes and the impact of minimally invasive surgery in early-stage cervical cancer patients undergoing radical trachelectomy: A retrospective multicenter cohort study from the Korean Gynecologic Oncology Group Study (KGOG 1048).
    Gynecol Oncol. 2026;208:113-121.
    >> Share

  179. LIU JB, He TX, Zeng C, Kaur MN, et al
    Association of surgical complexity with patient-reported outcomes among patients with ovarian cancer.
    Gynecol Oncol. 2026;208:106-112.
    >> Share

  180. BAKKUM-GAMEZ JN, Harrington SP, Slettedahl SW, Berger CK, et al
    Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.
    Gynecol Oncol. 2026;208:91-99.
    >> Share

  181. LEE J, Seo K, Kim J, Son JH, et al
    Evaluating alternative protocols for preventing cisplatin-induced acute kidney injury during hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Gynecol Oncol. 2026;208:85-90.
    >> Share

  182. FEDERICO A, Pisano G, Fragomeni SM, Pavone M, et al
    Lymphatic mapping and sentinel node biopsy in invasive Vulvar Paget's disease: A retrospective study and systematic review of the literature.
    Gynecol Oncol. 2026;207:57-65.
    >> Share

  183. HOCKEL M, Weydandt L, Wolf B, Keream EA, et al
    Peripheral immune network-directed dissection of lymph node regions (iLND): Novel surgical approach for the regional assessment and therapy of vulvar carcinoma.
    Gynecol Oncol. 2026;207:23-33.
    >> Share

  184. AGUSTI N, Rauh-Hain JA
    Same-day discharge in advanced ovarian cancer as a milestone of surgical evolution and patient selection.
    Gynecol Oncol. 2026;207:A1-A2.
    >> Share

  185. CHALIF J, Morton M, Gonzalez A, McLaughlin E, et al
    Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer.
    Gynecol Oncol. 2026;208:77-84.
    >> Share

  186. PARANJPE R, Chen C, Sun Y, Hong JL, et al
    Molecular heterogeneity of endometrial cancer in the real-world: Biomarker patterns by tumor stage, histology, and molecular subtype.
    Gynecol Oncol. 2026;208:69-76.
    >> Share

  187. BASHI A, Penvose KN, Wright JD, Blank SV, et al
    Cost and efficiency of universal versus selective next generation sequencing for advanced stage endometrial cancer.
    Gynecol Oncol. 2026;207S:67-73.
    >> Share

  188. LEVIN G, Gilbert L, Coleman RL, Meyer R, et al
    Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends.
    Gynecol Oncol. 2026;207S:60-66.
    >> Share

  189. KRIVENKO O, Diaz N, Richardson K, Antonio D, et al
    Impact of a community-centered intervention on knowledge, confidence, and attitudes toward clinical trials: A pilot survey study.
    Gynecol Oncol. 2026;207S:53-59.
    >> Share

  190. ROTHNIE K, Tristano E, Diaz-Rodriguez M, Filippova O, et al
    Expanded subtype testing for circulating tumor HPV DNA reliably detects the presence of advanced-stage cervical cancer.
    Gynecol Oncol. 2026;207S:47-52.
    >> Share

  191. EPSTEIN ES, Primiano M, Ozarowski AL, Karimaghaie T, et al
    ACT-ON: Assisted cascade testing via outreach and navigation - Real-world experience with clinician-facilitated cascade testing.
    Gynecol Oncol. 2026;207S:38-46.
    >> Share

  192. SAWAYA K, Maraghe M, Metzger S, Heming CM, et al
    Identifying ovarian cancer with AI analysis of abdominal CT scans.
    Gynecol Oncol. 2026;207S:30-37.
    >> Share

  193. VAN NIEUWENHUYSEN E, Vergote I, Randall LM, Tromp J, et al
    Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.
    Gynecol Oncol. 2026;207S:3-13.
    >> Share

  194. HSIEH TYJ, Yen TT, Hacker MR, Dottino J, et al
    Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.
    Gynecol Oncol. 2026;207S:23-29.
    >> Share

  195. LIU B, Chen J, Chen L, Chen X, et al
    Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.
    Gynecol Oncol. 2026;207S:14-22.
    >> Share


  196. Society of Gynecologic Oncology Annual Meeting Special Issue.
    Gynecol Oncol. 2026;207S:1.
    >> Share

    March 2026
  197. CHALIF J, Moruzzi C, Velasquez J, O'Connor R, et al
    Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility study.
    Gynecol Oncol. 2026;208:63-68.
    >> Share

  198. SCHREUDER GOEDHEIJT M, Aronson SL, Sonke GS, van Driel WJ, et al
    Influence of cardiophrenic lymph nodes on survival in patients receiving hyperthermic intraperitoneal chemotherapy for ovarian cancer in the OVHIPEC-1 trial.
    Gynecol Oncol. 2026;208:54-62.
    >> Share

  199. KAILASAM A, De Vitis L, Murphy B, Cucinella G, et al
    The progesterone paradigm: Molecular prognostication in conservative management of endometrial cancer.
    Gynecol Oncol. 2026;208:48-53.
    >> Share

  200. BORKAR SR, Tasman JG, Bakkum-Gamez JN, Cheney MC, et al
    Exploring delays in primary gynecologic and breast cancer diagnosis after emergency department presentation.
    Gynecol Oncol. 2026;208:41-47.
    >> Share

  201. BOYLE SJ, Dona A, Vogel RI, Argenta P, et al
    Long-term survival outcomes of robotic-assisted versus traditional laparoscopy for the treatment of stage I endometrial cancer: a National Cancer Database analysis.
    Gynecol Oncol. 2026;207:66-73.
    >> Share

  202. SALEHIPOUR D, Tadess B, Moore A, Jones T, et al
    Enhancing engagement in biobanking research among Black women with endometrial cancer.
    Gynecol Oncol. 2026;208:32-40.
    >> Share

  203. ALTAYF A, Nelson G, Chiva LM, Restaino S, et al
    The role of hyperthermic intraperitoneal chemotherapy in newly diagnosed and recurrent ovarian cancer: A time-to-event meta-analysis of randomized trials.
    Gynecol Oncol. 2026;208:22-31.
    >> Share

  204. FINCH L, Broach V, Long KC, Gardner GJ, et al
    Noncompete agreements in job contracts: Knowledge and opinion of practicing gynecologic oncologist members of Society of Gynecologic Oncology.
    Gynecol Oncol. 2026;208:17-21.
    >> Share

  205. LEE MW, Friedman EL, Erfani H, Keymeulen S, et al
    Assessment of survival and clinicopathologic characteristics associated with lymph node isolated tumor cells in epithelial ovarian cancer.
    Gynecol Oncol. 2026;207:50-56.
    >> Share

  206. NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
    Corrigendum to 'Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer' [Gynecologic Oncology 204 (2026) 184-193].
    Gynecol Oncol. 2026;207:48-49.
    >> Share

  207. BOU ZERDAN M, Saab R, Meyer LA, Munsell MF, et al
    Demographics, clinicopathological features, and survival outcomes of women with endometrial neuroendocrine tumors.
    Gynecol Oncol. 2026;207:34-39.
    >> Share

  208. MOREL D, Parvu V, Andrews J, Stephenson P, et al
    HPV genotype prevalence in low- and high-vaccine coverage, USA populations: Data from real-world cervical cancer screening using the Onclarity HPV assay.
    Gynecol Oncol. 2026;207:40-47.
    >> Share

  209. SAAB R, Brazan A, Chisholm GB, Gonzales NR, et al
    Clear cell carcinoma of cervix and vagina: A review of 63 cases in the post-DES era.
    Gynecol Oncol. 2026;206:39-44.
    >> Share

  210. FRAGOMENI SM, Collarino A, Federico A, Pisano G, et al
    Extending eligibility criteria for sentinel lymph node biopsy in vulvar cancer: An update on the GroSNaPET study.
    Gynecol Oncol. 2026;206:15-22.
    >> Share

  211. DWYER E, Kennedy L, Bethune D, Katz R, et al
    Granulosa cell tumors: Initial surgical approach and recurrence.
    Gynecol Oncol. 2026;206:9-14.
    >> Share

  212. ESKANDER RN, Lorusso D
    Hitting the mark-or missing it? The promise and peril of biomarkers in endometrial cancer.
    Gynecol Oncol. 2026;206:A1-A2.
    >> Share

    February 2026
  213. GUIJARRO-CAMPILLO AR, Gonzalez-Gil A, Gil-Gomez E, Olivares-Ripoll V, et al
    Rectosigmoidectomy versus pelvic peritonectomy in the management of seromuscular involvement of superficial rectal wall tumors in advanced-stage ovarian cancer at complete interval cytoreductive surgery.
    Gynecol Oncol. 2026;207:16-22.
    >> Share

  214. INAN M, Akar Inan S, Aypak C, Turkmen O, et al
    Emily vs. Lakisha: Quantifying socioeconomic and structural disparities in AI-generated ovarian cancer care plans.
    Gynecol Oncol. 2026;207:7-15.
    >> Share

  215. TEWARI S, Youssef A, Li S, Stewart T, et al
    Same day discharge after minimally invasive interval debulking surgery in advanced stage ovarian cancer.
    Gynecol Oncol. 2026;207:1-6.
    >> Share

  216. LEE KY, Tseng TH, Chang WC, Tai YJ, et al
    Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification.
    Gynecol Oncol. 2026;206:117-124.
    >> Share

  217. TALEBIAN N, Falah Tafti M, Alikarami S, Modugno F, et al
    Lifetime ovulations and endometrial cancer risk: A systematic review and meta-analysis.
    Gynecol Oncol. 2026;206:106-116.
    >> Share

  218. DAIX-MOREUX M, El Hajj H, Scherier S, Deandreis D, et al
    Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases.
    Gynecol Oncol. 2026;206:99-105.
    >> Share

  219. BESHAR I, Khorshid A, Somasegar S, Kennedy L, et al
    Pre-operative cross-sectional imaging of chest, abdomen, pelvis is not cost-effective for low-grade endometrial cancer.
    Gynecol Oncol. 2026;206:93-98.
    >> Share

  220. WANG X, Zheng L, Zhu G, Wang S, et al
    CDO1 and CELF4 methylation assay as the dominant predictor of endometrial cancer: A cohort analysis across pre- and post-menopausal cohorts.
    Gynecol Oncol. 2026;206:82-92.
    >> Share

  221. DUE LP, Ketabi Z, Hogdall C, Rasmussen ELK, et al
    Clinico-pathological characteristics of adult granulosa cell tumors of the ovary and the role of staging surgery: A national database study.
    Gynecol Oncol. 2026;206:74-81.
    >> Share

  222. PALMIERI L, Bellone S, Demirkiran C, Hartwich TMP, et al
    Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts.
    Gynecol Oncol. 2026;206:65-73.
    >> Share

  223. WESTIN SN, Moore K, Chon HS, Pepin JT, et al
    Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO- E/GOG-3041/ENGOT-EN10 trial
    Gynecol Oncol. 2026;206:54-64.
    >> Share

  224. GARKHAIL P, de Bruin PC, Boere IA, van der Aa MA, et al
    Survival benefit of platinum-based chemotherapy in non-surgically treated advanced ovarian cancer: A nationwide study.
    Gynecol Oncol. 2026;206:45-53.
    >> Share

  225. HODENT S, Bakrin N, Rousset P, Kepenekian V, et al
    Eco-responsible and rational interval debulking surgery for high-grade ovarian carcinomas: An observational, ambispective cohort study.
    Gynecol Oncol. 2026;206:32-38.
    >> Share

  226. VERMAAS EM, Wenzel HHB, van der Aa MA, Snijders M, et al
    Impact of COVID-19 on oncological outcomes during follow-up in gynaecological cancer: A nationwide retrospective cohort study.
    Gynecol Oncol. 2026;205:79-88.
    >> Share

  227. NAUMANN RW
    Commentary on: Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup Canadian Cancer Trials Group Cx.5/SHAPE tr
    Gynecol Oncol. 2026;205:A1-A2.
    >> Share

    January 2026
  228. SHERMAN ME, Pacheco-Spann L, Friedman S, Rose D, et al
    BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk.
    Gynecol Oncol. 2026;206:23-31.
    >> Share

  229. PEREZ L, Kulkarni A, Lopez S, Brewer JT, et al
    Understanding patient priorities: Sexual health and hereditary ovarian cancer syndromes.
    Gynecol Oncol. 2026;205:113-119.
    >> Share

  230. MATTHEWS BJ, Paskett ED, McLaughlin E, Von Ah D, et al
    Risk of memory impairment in gynecologic cancer survivors in the Women's Health Initiative: Untangling effects of age, comorbidities, and cancer.
    Gynecol Oncol. 2026;206:1-8.
    >> Share

  231. JAMIESON A, Rogan S, Zhang AW, Martin SD, et al
    Substratification of mismatch repair deficient endometrial cancers based on mechanism of MMR loss can provide prognostic and predictive refinement.
    Gynecol Oncol. 2026;205:105-112.
    >> Share

  232. BRODSKY AL, Tahan E, Celestino J, Tang X, et al
    Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors.
    Gynecol Oncol. 2026;205:99-104.
    >> Share

  233. WOHLRAB K, Robison K, Rahn DD, Dunivan GC, et al
    Safety and feasibility of concomitant urogynecologic and gynecologic oncology surgical procedures.
    Gynecol Oncol. 2026 Jan 22:S0090-8258(26)00007.
    >> Share

  234. JAIN D, Wahidi M, Effendi J, Hoang L, et al
    Survival comparison analysis between cervical squamous cell carcinoma and adenocarcinoma with a special focus on the HPV status.
    Gynecol Oncol. 2026;205:89-98.
    >> Share

  235. ROTHSCHILD H, Hillman RT
    New therapeutic strategies for relapsed adult type ovarian granulosa cell Tumors: From discovery to clinical progress.
    Gynecol Oncol. 2026 Jan 19:S0090-8258(26)00011.
    >> Share

  236. LINZ VC, Liebau E, Herrmann L, Schepers M, et al
    Association of preoperative G8 score with survival, preoperative anemia and vitamin D status in gynecologic cancer patients: 5-year analysis of the Frail-B study.
    Gynecol Oncol. 2026;205:70-78.
    >> Share

  237. SEERATAN DD, Jongkind A, van Lonkhuijzen LRCW, van Muilekom MM, et al
    Utilization of patient-reported outcome measures for women with low health literacy in gynecologic oncology - A mixed-methods study.
    Gynecol Oncol. 2026;205:53-62.
    >> Share

  238. CUTRI-FRENCH C, Saris DH, Solorzano SS, Wang X, et al
    Disparities in access to gynecologic oncology visits among elderly patients with gynecologic malignancies.
    Gynecol Oncol. 2026;205:63-69.
    >> Share

  239. MORGAN JE, Chen L, Xu X, Dioun S, et al
    Trends, predictors, and safety of ovarian preservation in premenopausal women with high-grade endometrioid and non-endometrioid endometrial cancers.
    Gynecol Oncol. 2026;205:46-52.
    >> Share

  240. KIM SI, Kim JW, Kwon JS, Ferguson SE, et al
    Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial.
    Gynecol Oncol. 2026;205:37-45.
    >> Share

  241. PARULEKAR M, Kim YN, Kim K, Lee S, et al
    Leveraging tumor multigene panel testing to identify germline variants in gynecologic cancers: A retrospective evaluation of an algorithm-based approach.
    Gynecol Oncol. 2026;205:32-36.
    >> Share

  242. SMITH HJ, Dinkins K, Liang MI, Chu DI, et al
    Feasibility of a mobile health platform for patient education and remote symptom monitoring in patients with advanced ovarian cancer undergoing primary chemotherapy.
    Gynecol Oncol. 2026;205:27-31.
    >> Share

  243. TANG W, Wang L, Li X, Yan X, et al
    Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer.
    Gynecol Oncol. 2026;205:17-26.
    >> Share

  244. FAN KY, Chehade R, Wang AY, Sachdeva A, et al
    Surgery versus definitive radiotherapy in the management of stage I-II small cell neuroendocrine carcinoma of the cervix: A systematic review and meta-analysis.
    Gynecol Oncol. 2026;204:118-123.
    >> Share

  245. RHIND M, Abdulhaleem K, Zhu R, Wei K, et al
    Exploring novel therapeutic targets in vulvar squamous cell carcinoma.
    Gynecol Oncol. 2026;204:63-69.
    >> Share

  246. DING M, Li X, Wang H, Jia X, et al
    G-M6, an oleanane triterpenoid, represents a novel scaffold for PARP1 inhibition and anticancer activity.
    Gynecol Oncol. 2026;204:9-16.
    >> Share

  247. ANNUNZIATA CM
    Towards personalizing PARP inhibitor maintenance therapy for ovarian cancer.
    Gynecol Oncol. 2026;204:A1-A2.
    >> Share

    December 2025
  248. LUDMIR D, Huang Y, Xu X, Dioun S, et al
    Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors.
    Gynecol Oncol. 2025;205:9-16.
    >> Share

  249. AHMED A, Saini G, Ferguson SE, Fazelzad R, et al
    Prognostic value of perioperative circulating tumor DNA in endometrial cancer: systematic review & meta-analysis.
    Gynecol Oncol. 2025;205:1-8.
    >> Share

  250. LESNOCK J, Gaillard S, Tew WP
    ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
    Gynecol Oncol. 2025;204:251-253.
    >> Share

  251. LIM JW, Drost L, Fazelzad R, Li Q, et al
    MLH1 promoter hypermethylated endometrial cancer survival outcomes: A systematic review and meta-analysis.
    Gynecol Oncol. 2025;204:242-250.
    >> Share

  252. MAESTA I, Silva VAR, Costa RAA, Carvalho TH, et al
    Home-based treatment of low-risk gestational trophoblastic neoplasia with 8-day methotrexate/folinic acid.
    Gynecol Oncol. 2025;204:235-241.
    >> Share

  253. PATTERSON B, Sinha N, Broaddus E, Stocks S, et al
    Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer.
    Gynecol Oncol. 2025;204:228-234.
    >> Share

  254. WASHINGTON C, Pothuri B, Cadoo K, Drew Y, et al
    Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review.
    Gynecol Oncol. 2025;204:218-227.
    >> Share

  255. FERNANDES I, Sachdeva A, Tavangar F, Lafreniere M, et al
    Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.
    Gynecol Oncol. 2025;204:210-217.
    >> Share

  256. SHAHIN MS, Mathur R, Parthan A, Yerram P, et al
    Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS).
    Gynecol Oncol. 2025;204:202-209.
    >> Share

  257. PEPLINSKI RM, Riordan JD, Schillo JL, Hannan EC, et al
    Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines.
    Gynecol Oncol. 2025;204:194-201.
    >> Share

  258. NAKAYAMA J, McGaughey M, Pindzola G, Miller E, et al
    Machine-learning survival models for predicting time to recurrence in epithelial ovarian cancer.
    Gynecol Oncol. 2025;204:184-193.
    >> Share

  259. EVANS HE, Firriolo AM, Houweling R, Kelada L, et al
    Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study.
    Gynecol Oncol. 2025;204:150-157.
    >> Share

  260. MATSUO K, Lee MW, Friedman EL, Erfani H, et al
    Survival assessment of sentinel lymph node biopsy alone without lymphadenectomy for early cervical cancer in real-world data.
    Gynecol Oncol. 2025;204:174-183.
    >> Share

  261. LIM S, Chung YE, Seo JH, Lee Y, et al
    Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study.
    Gynecol Oncol. 2025;204:165-173.
    >> Share

  262. WANG Y, Van Nieuwenhuysen E, Revheim ME, Deroose CM, et al
    First experience with intraperitoneal (224)Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
    Gynecol Oncol. 2025;204:158-164.
    >> Share

  263. HANSEN J, Suratkal J, Shah SN, Kelley J, et al
    Frailty and body composition as predictors of postoperative outcomes in patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2025;204:143-149.
    >> Share

  264. KRAICZY J, Yu B
    Human fallopian tube epithelial organoids with TP53 mutation recapitulate features of serous tubal intraepithelial carcinoma (STIC).
    Gynecol Oncol. 2025;203:198-208.
    >> Share

  265. LU H, Wang Y, Chang L, Liu J, et al
    Treatment patterns and prognosis of patients with locally advanced vulvar cancer: a retrospective cohort study of the SEER database and a Chinese multicenter registry.
    Gynecol Oncol. 2025;203:171-181.
    >> Share

  266. VERMAAS EM, Roling P, Konior KM, Wenzel HHB, et al
    Reconsidering follow-up care in gynaecologic oncology: A scoping review exploring alternative approaches.
    Gynecol Oncol. 2025;203:139-150.
    >> Share

  267. FAN Y, Wang Q, Deng H, Liu Y, et al
    Neoadjuvant chemotherapy modulates mast cell phenotypes and immune infiltration in high-grade serous carcinoma.
    Gynecol Oncol. 2025;203:119-129.
    >> Share

  268. DHANIS J, Pijnenborg JMA, van Laarhoven CJHM, Verlaan S, et al
    The effect of a multimodal prehabilitation programme on preoperative physical fitness and nutritional status of women with gynaecological cancer.
    Gynecol Oncol. 2025;203:1-7.
    >> Share

  269. NISHA M, Liang YL, Bateson D, Saville M, et al
    Optimising management of women with HPV (not 16/18): Findings from a national HPV screening program.
    Gynecol Oncol. 2025;204:133-142.
    >> Share

    November 2025
  270. JOHNSON RL, Mappa G, Gahir N, Allen KE, et al
    Prognostic and immunological significance of tryptophan metabolic enzymes across endometrial cancer molecular subtypes.
    Gynecol Oncol. 2025;204:124-131.
    >> Share

  271. SALANI R, Atallah D, Fader AN, Frimer M, et al
    Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2025;204:109-117.
    >> Share

  272. SOPPE SE, Kuo TM, Lyratzopoulos G, DeRouen MC, et al
    Symptom-related care and diagnoses before ovarian cancer detection: Patterns and differences by cancer stage.
    Gynecol Oncol. 2025;204:100-108.
    >> Share

  273. EVERT JSH, de Jonge PKJD, Zusterzeel PLM, Hobo W, et al
    Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
    Gynecol Oncol. 2025;204:91-99.
    >> Share

  274. CUN HT, Bedell SM, Kimball J, Gaffney DK, et al
    Radiation therapy for the gynecologic oncologist.
    Gynecol Oncol. 2025;204:79-90.
    >> Share

  275. HAYAKAWA M, Nakajima H, Harano K, Watanabe S, et al
    Impact of platinum-free interval and bevacizumab on second-line chemotherapy following progression on first-line PARP inhibitor maintenance in advanced ovarian cancer: A retrospective cohort study.
    Gynecol Oncol. 2025;204:70-78.
    >> Share

  276. TANKOU J, Ruau S, Walia A, Toboni M, et al
    AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
    Gynecol Oncol. 2025;204:52-62.
    >> Share

  277. SHI Y, Gkekos L, Rodriguez-Wallberg KA, Fredriksson I, et al
    Obstetric and perinatal outcomes following a diagnosis of gynecologic cancer during pregnancy.
    Gynecol Oncol. 2025;204:44-51.
    >> Share

  278. TOBONI MD, Evans ET, Scalise CB, Hardesty M, et al
    Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
    Gynecol Oncol. 2025;204:37-43.
    >> Share

  279. LEE AJ, Jang EB, Suh DH, Chang SJ, et al
    Comparison of oncologic outcomes between completion hysterectomy and no completion hysterectomy in patients who achieved complete response and completed childbearing after fertility-sparing treatment for early-stage endometrial cancer: Gynecologic Onc
    Gynecol Oncol. 2025;203:191-197.
    >> Share

  280. BAO W, He X, Huang Y, Xing A, et al
    Effect of uterine manipulator on stage IB1 to IIA1 cervical cancer: A retrospective cohort study.
    Gynecol Oncol. 2025;204:27-36.
    >> Share

  281. ARIOLA AB, Nolan B, Johnson L, Cunningham MJ, et al
    The impact of cervical diameter on success of sentinel lymph node mapping in endometrial carcinoma: A retrospective cohort study.
    Gynecol Oncol. 2025;204:23-26.
    >> Share

  282. FURUYA RL, Grither W, Evans MG, Wu S, et al
    Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial carcinoma.
    Gynecol Oncol. 2025;204:17-22.
    >> Share

  283. ARYASOMAYAJULA C, Johnson CR, Francoeur AA, Sia TY, et al
    Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study.
    Gynecol Oncol. 2025;204:1-8.
    >> Share

  284. CHUNG YE, Kim SI, Noh JJ, Lee JY, et al
    Immune checkpoint inhibitors for recurrent ovarian clear cell carcinoma: Real-world outcomes from a Korean multicenter study.
    Gynecol Oncol. 2025;203:185-190.
    >> Share

  285. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    Corrigendum to 'HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study' [Gynecologic Oncology 194 (2025) 33-40].
    Gynecol Oncol. 2025;203:184.
    >> Share

  286. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
    Corrigendum to 'OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer' [Gynecol Oncol 2025 Jun 19
    Gynecol Oncol. 2025;203:182-183.
    >> Share

  287. TISCHER KM, Islam NS, McGree ME, Tapia AL, et al
    Quantifying opportunities to reduce high grade serous ovarian cancer via opportunistic salpingectomy.
    Gynecol Oncol. 2025;203:165-170.
    >> Share

  288. WASHINGTON C, Dwivedi SKD, Gunderson-Jackson C, Walker J, et al
    Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
    Gynecol Oncol. 2025;203:158-164.
    >> Share

  289. PARK J, Lee D, Kim S, Kim YN, et al
    Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.
    Gynecol Oncol. 2025;203:151-157.
    >> Share

  290. BASHI A, Chen L, Rouse K, Elkin EB, et al
    Cost-effectiveness of biomarker-based and universal strategies for the treatment of advanced-stage endometrial cancer.
    Gynecol Oncol. 2025;203:130-138.
    >> Share

  291. DRAYER SM, Ogata JD, Cronin S, Tumas J, et al
    Silva pattern-guided proteomics reveals coordinated tumor-stroma remodeling in cervical adenocarcinoma.
    Gynecol Oncol. 2025;202:66-76.
    >> Share

  292. MILMAN T, Hoang L, Hamm J, Chai J, et al
    Real-world utility of Silva pattern in predicting outcomes in cervical adenocarcinoma from a population-based series.
    Gynecol Oncol. 2025;202:53-58.
    >> Share

  293. HUANG M, McCourt C, Powell MA, Lu KH, et al
    Amplifying SGO'S voice: The impact of the Society of Gynecologic Oncology (SGO) clinical practice committee publications in Gynecologic Oncology.
    Gynecol Oncol. 2025;202:A1-A2.
    >> Share

    October 2025
  294. MOUFARRIJ S, Friedman CF, Freeman S, Green H, et al
    A pilot study of nivolumab in combination with neoadjuvant and post-surgical chemotherapy in newly diagnosed ovarian cancer.
    Gynecol Oncol. 2025;203:97-104.
    >> Share

  295. WHITE VM, Langdale LM, Eroh KD, Ackermann MK, et al
    Experiences of radiotherapy for treatment of Granulosa Cell Tumor of the ovary: insights from the GCT-survivor sisters.
    Gynecol Oncol. 2025;203:112-118.
    >> Share

  296. NOZAKI T, Sakamoto I, Kagami K, Matsuda K, et al
    Preoperative molecular classification of endometrial cancer: Validation through biopsy and matched hysterectomy specimens.
    Gynecol Oncol. 2025;203:105-111.
    >> Share

  297. LINDGREN A, Benseler A, Hogen L, May T, et al
    Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment.
    Gynecol Oncol. 2025;203:90-96.
    >> Share

  298. ARAUJO LW, Maliniak ML, Barber LE, Dilley SE, et al
    Neighborhood socioeconomic status and endometrial cancer mortality: Racial disparities persist across the spectrum.
    Gynecol Oncol. 2025;203:84-89.
    >> Share

  299. XU X, Chen L, Nunez-Smith M, Clark M, et al
    Postmenopausal bleeding: Association of initial place of care with stage at diagnosis for uterine cancer.
    Gynecol Oncol. 2025;203:75-83.
    >> Share

  300. WANG Y, Li J, Yang Y, Lu X, et al
    Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study.
    Gynecol Oncol. 2025;203:67-74.
    >> Share

  301. SKOLD C, Radestad AF, Bohlin KS, Bjurberg M, et al
    Primary treatment and survival in malignant ovarian germ cell tumors: A nationwide population-based Swedish Gynecologic Cancer Group (SweGCG) study.
    Gynecol Oncol. 2025;203:59-66.
    >> Share

  302. TEWARI S, Koelker-Wolfe E, Pelletier A, St Laurent J, et al
    The impact of romiplostim use for chemotherapy induced thrombocytopenia on immediate and long-term outcomes in gynecologic malignancies.
    Gynecol Oncol. 2025;203:53-58.
    >> Share

  303. ANDRES S, Tannous A, Kahn RM, Yeoshoua E, et al
    Survival outcomes in patients receiving neoadjuvant chemotherapy for advanced ovarian cancer: Does the indication for neoadjuvant chemotherapy matter?
    Gynecol Oncol. 2025;203:35-42.
    >> Share

  304. MANNING B, Banerjee S, Hawkins TB, Winn-Deen ES, et al
    Extracellular vesicle and particle-based blood test for ovarian cancer screening of average risk population: a promising nested case control study using preclinical samples.
    Gynecol Oncol. 2025;203:26-34.
    >> Share

  305. MACHIDA H, Kawana K, Okamoto A, Yamagami W, et al
    Impact of neoadjuvant chemotherapy followed by interval debulking surgery on survival in women with advanced non-serous ovarian, fallopian tube, or primary peritoneal cancer.
    Gynecol Oncol. 2025;203:8-15.
    >> Share

  306. HOTTON J, Gaillard T, Paoletti X, Raimond E, et al
    Survival impact of residual disease and timing of surgery in the management of advanced-stage low grade serous ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2025;203:16-25.
    >> Share

  307. MAURER T, Belau MH, Zyriax BC, Welsch G, et al
    Development and optimization of an integrated exercise and nutrition program for ovarian cancer patients: Phase I of the BENITA multi-center study.
    Gynecol Oncol. 2025;202:167-173.
    >> Share

  308. HOLTZMAN S, Myers E, Havrilesky LJ, Yamada D, et al
    Gynecologic oncology fellowship trends: Supply outpacing demand, geographical maldistribution.
    Gynecol Oncol. 2025;202:162-166.
    >> Share

  309. DAGHER C, Selenica P, Bakhuis CFJ, Green H, et al
    Prognostic value of positive peritoneal cytology in FIGO 2009 stage IA grade 1 endometrioid endometrial cancer.
    Gynecol Oncol. 2025;202:154-161.
    >> Share

  310. KIM U, Oh BC, Bae J, Kang S, et al
    Survival outcomes and treatment patterns in malignant ovarian sex cord-stromal tumors: A population-based analysis.
    Gynecol Oncol. 2025;202:146-153.
    >> Share

  311. POWELL CA, Winer IS, Tarney CM, Gaillard S, et al
    Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.
    Gynecol Oncol. 2025;202:137-145.
    >> Share

  312. ETTORRE VM, Bellone S, Buza N, Hui P, et al
    Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis.
    Gynecol Oncol. 2025;202:131-136.
    >> Share

  313. BORDEN BA, Rodriguez-Hernandez A, Trottier M, Horiguchi M, et al
    SMARCA4 pathogenic variants: Gynecological cancer histories from a laboratory tested cohort.
    Gynecol Oncol. 2025;202:125-130.
    >> Share

  314. KOCIAN R, Kohler C, Klat J, Jarkovsky J, et al
    Sentinel lymph node mapping in early-stage cervical cancer: Results from the SENTIX prospective multicenter study.
    Gynecol Oncol. 2025;202:118-124.
    >> Share

  315. GARG V, Armstrong E, Celeste A, Wang C, et al
    Multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program in patients with advanced gynecological cancers: A prospective study.
    Gynecol Oncol. 2025;202:110-117.
    >> Share

  316. LIM JW, Dzyubak O, Moshkovich M, Maganti M, et al
    Impact of FIGO 2023 staging criteria on stage migration and survival outcomes in early-stage endometrial cancer: A retrospective cohort study.
    Gynecol Oncol. 2025;202:93-101.
    >> Share

  317. CHASE DM, Huang HQ, Deng W, Koh WJ, et al
    Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-026
    Gynecol Oncol. 2025;202:102-109.
    >> Share

  318. NEPHEW KP, Drapkin R, Lang J, Zhuravlev Y, et al
    The 15th Biennial Rivkin Center ovarian cancer research symposium.
    Gynecol Oncol. 2025;201:A1-A2.
    >> Share

  319. KHADRAOUI W, Felix AS, Meade CE, Chalif J, et al
    Prognostic and demographic patterns in serous tubal intraepithelial carcinoma: A National Cancer Database study.
    Gynecol Oncol. 2025;201:76-82.
    >> Share

  320. BLANK SV, Frey MK
    Does a diagnosis of breast cancer reduce ovarian cancer risk in BRCA1/2 3 carriers: Why is this a question?
    Gynecol Oncol. 2025;201:A3-A4.
    >> Share

    September 2025
  321. JANKE MJ, Minns A, Pesce MM, McLaughlin HD, et al
    Trends in pre-fellowship research productivity among matched gynecologic oncology fellows.
    Gynecol Oncol. 2025;202:87-92.
    >> Share

  322. GERSHENSON DM, Burns K, Sun C
    Update on contemporary treatment for newly diagnosed stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC).
    Gynecol Oncol. 2025;202:85-86.
    >> Share

  323. SIA TY, Brown DN, Miller K, Curtin C, et al
    Uterine leiomyosarcoma progression: A study of serial recurrences.
    Gynecol Oncol. 2025;202:77-84.
    >> Share

  324. SOMASEGAR S, Zhang J, Fotopoulou C, Fumagalli D, et al
    The role of neoadjuvant chemotherapy in advanced-stage clear cell ovarian cancer: A GCIG multi-institutional retrospective cohort study.
    Gynecol Oncol. 2025;202:59-65.
    >> Share

  325. GENG F, Wang Y, Cui G, Fan M, et al
    TRIB3 promotes endometrial cancer progression through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis.
    Gynecol Oncol. 2025;202:41-52.
    >> Share

  326. AN J, Li G, Zhang Y, Feng M, et al
    Sacituzumab govitecan in Chinese patients with recurrent/metastatic cervical cancer: Results from the phase 2 EVER-132-003 basket study (NCT05119907).
    Gynecol Oncol. 2025;202:33-40.
    >> Share

  327. SUGIYAMA Y, Kosugi M, Gotoh O, Tonooka A, et al
    Genomic and DNA methylomic factors associated with the efficacy of oral medroxyprogesterone acetate on endometrial neoplastic disease.
    Gynecol Oncol. 2025;202:24-32.
    >> Share

  328. YOH K, Desai VB, Gross CP, Spatz ES, et al
    Physician variation in adopting opportunistic salpingectomy at the time of postpartum and interval sterilization for ovarian cancer risk reduction.
    Gynecol Oncol. 2025;202:1-13.
    >> Share

  329. VAN DEN BORST E, Vanden Broeck D, De Sutter P, Donders G, et al
    EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol.
    Gynecol Oncol. 2025;202:14-23.
    >> Share

  330. LOUKOVAARA M, Pasanen A, Butzow R
    Distinct clinical outcomes according to molecular subgroups in relapsed endometrial carcinoma: A cohort study.
    Gynecol Oncol. 2025;201:216-222.
    >> Share

  331. ACKROYD SA, Sudilovsky G, Che Y, Wesevich A, et al
    Race and neighborhood disadvantage in patients with stage I-III endometrioid endometrial carcinoma treated at a tertiary referral center.
    Gynecol Oncol. 2025;201:203-209.
    >> Share

  332. FULGIONE C, Inzani F, Raffone A, Raimondo D, et al
    Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2025;201:210-215.
    >> Share

  333. ETTORRE VM, Demirkiran C, Bellone S, Hartwich TMP, et al
    Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts.
    Gynecol Oncol. 2025;201:195-202.
    >> Share

  334. MATSUO K, Enserro DM, Wright JD, Roman LD, et al
    Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
    Gynecol Oncol. 2025;201:184-194.
    >> Share

  335. LIN Z, Liu Z, Chen J, Gu H, et al
    Novel anatomical concept and standardized technique for single-port Paraaortic lymphadenectomy in gynecological cancers.
    Gynecol Oncol. 2025;201:176-183.
    >> Share

  336. REBOUILLAT C, Pomel C, Bourdel N, Mimoun C, et al
    Diagnostic laparoscopy and cytoreduction surgery in ovarian cancer FIGO III-IV: The impact on survival of one-stage versus two-stage sequence.
    Gynecol Oncol. 2025;201:167-175.
    >> Share

  337. CHIAPPINELLI KB, Christie EL, Padmanabhan A
    Biology of ovarian cancer: Models, microenvironment, and therapeutics: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:160-163.
    >> Share

  338. ZHOU N, Beavis AL, Lin LL, Neibart SS, et al
    Embracing and implementing the WHO cervical cancer elimination campaign goals: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS on minimum quality care standards for cervical cancer patients in the U.S.
    Gynecol Oncol. 2025;200:193-202.
    >> Share

  339. NEIBART S, Zhou N, Chino J, Earles T, et al
    Health equity, disparities, and barriers to cervical cancer care in the U.S.: A consensus statement by SGO, ACOG, ASCCP, ASTRO, and ABS addressing the WHO cervical Cancer elimination campaign goals related to treatment.
    Gynecol Oncol. 2025;200:186-192.
    >> Share

  340. NEIBART SS, Lin LL, Einstein MH, Teoh D, et al
    Minimum standards for radiation therapy in the treatment of cervical cancer in the U.S.: A consensus statement by SGO, ASTRO, and ABS addressing the WHO Cervical Cancer Elimination Campaign goals.
    Gynecol Oncol. 2025;200:180-185.
    >> Share

  341. MATSUBARA M, Otani T, Kawakami F, Koike A, et al
    Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group.
    Gynecol Oncol. 2025;200:112-121.
    >> Share

  342. SCHAAFSMA M, Schuurman TN, Bekkers RLM, Dunne FR, et al
    The risk for residual AIS/CIN3+ after the first conservative surgical procedure for cervical adenocarcinoma in situ - A Dutch retrospective cohort study.
    Gynecol Oncol. 2025;200:44-50.
    >> Share

  343. JAEGER A, Hampl M, Prieske K, Eulenburg C, et al
    Risk for non-sentinel metastases in the contralateral groin in patients with a unilateral positive sentinel lymph node in primary vulvar cancer- a subgroup analysis of the AGO-VOP.2 QS Vulva Study.
    Gynecol Oncol. 2025;200:8-13.
    >> Share

  344. MULLEN MM, Arend RC
    From one-size-fits all to biology-driven care: Emerging paradigms in gynecologic oncology.
    Gynecol Oncol. 2025;200:A1-A2.
    >> Share

    August 2025
  345. BRODSKY AL, Welte T, Vuttaradhi VK, Yang X, et al
    Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models.
    Gynecol Oncol. 2025;201:152-159.
    >> Share

  346. MORTON M, Chalif J, Sciuva J, Fulton J, et al
    The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapy.
    Gynecol Oncol. 2025;201:144-151.
    >> Share

  347. BRUCE KH, Xu C, Shah RP, McGree ME, et al
    Real-world outcomes of neoadjuvant chemotherapy for advanced ovarian cancer: What happens to patients who never undergo surgery?
    Gynecol Oncol. 2025;201:137-143.
    >> Share

  348. ANDRES S, Brown DN, Da Cruz Paula A, Aghajanian C, et al
    Whole-genome sequencing-based characterization of endometrial serous carcinoma.
    Gynecol Oncol. 2025;201:130-136.
    >> Share

  349. CHERRY DR, Gupta V, Bloom JR, Hsieh K, et al
    Early-stage uterine papillary serous carcinoma: Clinical outcomes in patients treated with adjuvant chemotherapy and vaginal brachytherapy.
    Gynecol Oncol. 2025;201:123-129.
    >> Share

  350. SMITH AJ, Acharya R, Ang L, Moore T, et al
    "What you're hearing from all of us is simplify the language": Patient perspectives on biomarker testing in ovarian cancer.
    Gynecol Oncol. 2025;201:118-122.
    >> Share

  351. SOONG TR, Islam BN, Hunt K, Nadeem A, et al
    Research is care: How patients and researchers can work together to bring the bedside back to the bench - a patient advocacy panel discussion: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:114-117.
    >> Share

  352. PERELMUTER S, Leung AC, Ahsan MD, Webster EM, et al
    Virtual versus reality: Assessing the accuracy of a digital cancer risk assessment tool in a gynecologic oncology clinic.
    Gynecol Oncol. 2025;200:169-174.
    >> Share

  353. LANITI DD, Verma P
    State-of-the art in emerging therapeutics for ovarian cancer therapy.
    Gynecol Oncol. 2025;201:109-113.
    >> Share

  354. ZHANG N, Porter RL
    Emerging approaches to enhance immune responses in ovarian cancer: 15th biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:97-101.
    >> Share

  355. GAILLARD S, Alvarez J, Zhang T, Wang H, et al
    A randomized pilot study of HPV16 L2E7E6 fusion protein vaccination site post-treatment for HPV16+ cervical cancer.
    Gynecol Oncol. 2025;201:86-96.
    >> Share

  356. SOZEN H, Minareci Y, Toyran A, Tutar E, et al
    Evaluation of total retroperitoneal en-bloc resection of multivisceral-peritoneal packet (TROMP) in advanced ovarian cancer: A single-center cohort study.
    Gynecol Oncol. 2025;201:102-108.
    >> Share

  357. ROBIN TP, Hu J, Jones BL, Patton T, et al
    Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer.
    Gynecol Oncol. 2025;200:175-179.
    >> Share

  358. GASPAR-MAIA A, Sasamoto N
    Prevention, early detection & interception: 15th biennial ovarian cancer research symposium.
    Gynecol Oncol. 2025;201:83-85.
    >> Share

  359. CORR BR, Thomas SM, Haight PJ, Stock E, et al
    Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability.
    Gynecol Oncol. 2025;201:69-75.
    >> Share

  360. SIA TY, Moufarrij S, Milani J, Kane S, et al
    Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?
    Gynecol Oncol. 2025;201:60-68.
    >> Share

  361. BRUBAKER LW, Merritt MA
    Ovarian cancer health disparities: 15th Biennial Rivkin Center Ovarian Cancer Research Symposium.
    Gynecol Oncol. 2025;201:56-59.
    >> Share

  362. FITCH KC, Previs RA, Moss HA
    The promise and perils of biomarker testing in gynecologic cancers.
    Gynecol Oncol. 2025;201:53-55.
    >> Share

  363. APOSTOL AI, Kotsopoulos J, Gronwald J, Kim RH, et al
    Ovarian cancer after breast cancer in women with a BRCA1 or BRCA2 pathogenic variant.
    Gynecol Oncol. 2025;201:44-52.
    >> Share

  364. NG ZY, McCluggage WG, Dundr P, Borcinova M, et al
    Evaluation of the significance of isolated tumor cells in gynecological cancers.
    Gynecol Oncol. 2025;201:40-43.
    >> Share

  365. POLEN-DE CL, Giannini A, Langstraat CL, Moreno AG, et al
    Effect of conization, manipulator use, and their interaction on recurrence after radical hysterectomy for cervical cancer: A multicenter retrospective analysis.
    Gynecol Oncol. 2025;201:33-39.
    >> Share

  366. TOWNER M, Grace A, Marcus J
    Beating cancer while building families: A mixed methods study on parenting, life choices, and career trajectories of gynecologic oncologists in the United States.
    Gynecol Oncol. 2025;201:26-32.
    >> Share

  367. CHATOR C, Chevrier M, Frenel JS, Guyon F, et al
    Role of platinum-free interval (PFI) and maintenance therapies in recurrent ovarian cancer to explain survival. An analysis from the French real-world ESME Ovarian Database.
    Gynecol Oncol. 2025;201:17-25.
    >> Share

  368. SPENARD E, Lin Y, Covens A, Gien LT, et al
    Optimizing the screening and management of preoperative anemia prior to gynecologic oncology surgery (OPRA1): A quality improvement initiative.
    Gynecol Oncol. 2025;201:7-16.
    >> Share

  369. HACKER KE, A Fleming K, Gupta M, Pothuri B, et al
    HER2 expression in an endometrial cancer cohort.
    Gynecol Oncol. 2025;201:1-6.
    >> Share

  370. BOGANI G, Fagotti A, Chiantera V, De Iaco P, et al
    The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Gynecol Oncol. 2025;200:161-168.
    >> Share

  371. WANG Y, Jia Z, Jiao J, Yue X, et al
    Analysis of the use of prophylactic ureteral stents in preventing iatrogenic ureteral injury during radical hysterectomy for cervical Cancer.
    Gynecol Oncol. 2025;200:155-160.
    >> Share

  372. MARCHETTI M, Vezzaro T, Carollo M, Facchetti E, et al
    The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer.
    Gynecol Oncol. 2025;200:145-154.
    >> Share

  373. CLARKE MA, Wentzensen N, Kobel M, Erickson BK, et al
    Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019.
    Gynecol Oncol. 2025;200:137-144.
    >> Share

  374. RISHI A, Albuquerque KV, Jhingran A, Donovan EK, et al
    Definitive intensity-modulated radiotherapy for organ preservation in vulvar cancer: A multicenter study.
    Gynecol Oncol. 2025;199:1-9.
    >> Share

    July 2025
  375. BRODSKY AL, Sun C, Cobb L, Westin SN, et al
    Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon: A clinicopathologic study of 39 cases.
    Gynecol Oncol. 2025;200:130-136.
    >> Share

  376. WANG JY, Simons EJ, Dingel A, Pike MM, et al
    Impact of chemotherapy provider specialty on outcomes in ovarian cancer.
    Gynecol Oncol. 2025;200:122-129.
    >> Share

  377. LIGHTFOOT MDS, Sinnott JA, Meade CE, Barrington DA, et al
    Enhancing predictive accuracy: Assessing the laparoscopic hysterectomy readmission score in a diverse endometrial cancer population.
    Gynecol Oncol. 2025;200:105-111.
    >> Share

  378. LEE KJ, Chokshi S, Joshi T, Cummings M, et al
    Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage.
    Gynecol Oncol. 2025;200:80-87.
    >> Share

  379. MATULONIS UA, Vergote I, Moore KN, Martin LP, et al
    Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2025;200:96-104.
    >> Share

  380. RAGLAND K, Pogue J, Simiele E, Simiele S, et al
    The use of transrectal ultrasound to improve gynecologic interstitial applicator implantation.
    Gynecol Oncol. 2025;200:88-95.
    >> Share

  381. MCGAURAN M, Hyde S, Perera S, Lloyd M, et al
    Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study.
    Gynecol Oncol. 2025;200:72-79.
    >> Share

  382. CORR BR, Haggerty A, Gysler SM, Taylor S, et al
    A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.
    Gynecol Oncol. 2025;200:58-67.
    >> Share

  383. PESCE M, Tondo-Steele K, Stroup C, Straubhar A, et al
    Persistent opioid use among gynecologic oncology patients after surgery.
    Gynecol Oncol. 2025;200:68-71.
    >> Share

  384. LAVEN P, Wenzel HHB, van der Aa MA, Lambrechts S, et al
    Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study.
    Gynecol Oncol. 2025;200:51-57.
    >> Share

  385. CARUSO G, Ainio C, Fumagalli D, Reynolds EA, et al
    Textbook oncologic outcome in endometrial cancer surgery: A quality measure to improve survival and address disparities.
    Gynecol Oncol. 2025;200:33-43.
    >> Share

  386. HE SY, Shen HW, Xu L, Zhao XH, et al
    Corrigendum to "FOXM1 promotes tumor cell invasion and correlates with poor prognosis in early-stage cervical cancer" [Gynecologic Oncology 127 (2012) 601-610].
    Gynecol Oncol. 2025 Jul 17:S0090-8258(25)00897.
    >> Share

  387. STOVER EH, Lee EK, Shapiro GI, Brugge JS, et al
    The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.
    Gynecol Oncol. 2025;200:22-32.
    >> Share

  388. KOIKE Y, Fujiwara A, Seki T, Kochi Y, et al
    The detrimental impact of diverting ileostomy on renal function after tumor debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;200:14-21.
    >> Share

  389. HUBINETTE M, Sundstrom-Poromaa I, Persson S, Elenis E, et al
    Polycystic ovary syndrome and the risk of ovarian tumours.
    Gynecol Oncol. 2025;200:1-7.
    >> Share

  390. LEE SS, Secord AA, Friedman S, Hade EM, et al
    Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therap
    Gynecol Oncol. 2025;199:152-158.
    >> Share

  391. BEKTAS O, Bektas K
    Prognostic value of systemic inflammatory markers in predicting neoadjuvant platinum response and platinum resistance in advanced epithelial ovarian cancer: A peritoneal cancer index-based analysis.
    Gynecol Oncol. 2025;199:147-151.
    >> Share

  392. RODRIGUEZ VE, Ro A, Hoyt MA, Tanjasiri SP, et al
    Racial/ethnic disparities in time from diagnosis to surgical treatment for type I and type II endometrial carcinomas.
    Gynecol Oncol. 2025;199:139-146.
    >> Share

  393. AINIO C, Rosanu M, Ribero L, Caruso G, et al
    Surgical complexity and scope of procedures necessary after neoadjuvant chemotherapy for primary ovarian cancer.
    Gynecol Oncol. 2025;199:133-138.
    >> Share

  394. SU H, Shang X, Liu H, Tian M, et al
    Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105).
    Gynecol Oncol. 2025;199:124-132.
    >> Share

  395. SILBERMAN JN, Benjamin A, Solk P, Matei D, et al
    Fit4Surgery: A pilot randomized controlled trial to assess the feasibility of prehabilitation prior to debulking surgery for ovarian cancer.
    Gynecol Oncol. 2025;199:116-123.
    >> Share

  396. LIANG MI, Aviki EM, Agarwal R, Dholakia J, et al
    What are we worth? An SGO analysis of compensation structures that measure and value work in academic gynecologic oncology practices.
    Gynecol Oncol. 2025;199:108-115.
    >> Share

  397. JOHNSON B, Milicia A, Hicks J, Hoskins E, et al
    Delays, fragmentation, and desire for alternatives: A qualitative study of the patient experience through diagnosis and treatment of endometrial cancer.
    Gynecol Oncol. 2025;199:103-107.
    >> Share

  398. HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
    A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
    Gynecol Oncol. 2025;199:96-102.
    >> Share

    June 2025
  399. RANDALL L, Xiang Y, Matsumoto T, Giannarelli D, et al
    Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
    Gynecol Oncol. 2025;199:88-95.
    >> Share

  400. LINDEMANN K, Berton D, Sehouli J, Christensen RD, et al
    NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2025;199:79-87.
    >> Share

  401. DZYUBAK O, Glass K, Watts M, Tarafdar O, et al
    Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
    Gynecol Oncol. 2025;199:72-78.
    >> Share

  402. GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
    Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
    Gynecol Oncol. 2025;199:64-71.
    >> Share

  403. WANG M, Dong T, Lucero M, Pan W, et al
    Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
    Gynecol Oncol. 2025;199:57-63.
    >> Share

  404. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.
    Gynecol Oncol. 2025;199:47-50.
    >> Share

  405. KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
    Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
    Gynecol Oncol. 2025;199:40-46.
    >> Share

  406. VARGIU V, Rosati A, Santullo F, Figa M, et al
    REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;199:32-39.
    >> Share

  407. LIU Y, Zhou Y, Zhou Z, Rao X, et al
    GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort study.
    Gynecol Oncol. 2025;199:27-31.
    >> Share

  408. WEI TY, Wu CC, Hsu YT, Lin WH, et al
    An exploratory analysis of driver gene alterations and their potential prognostic relevance in endometrial cancer with POLE exonuclease domain mutations.
    Gynecol Oncol. 2025;199:17-26.
    >> Share

  409. BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
    Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
    Gynecol Oncol. 2025;199:10-16.
    >> Share

  410. HUEPENBECKER SP, Iniesta MD, Munsell MF, Mandayam S, et al
    No increase in chronic kidney disease after postoperative acute kidney injury in gynecologic oncologic ERAS surgery.
    Gynecol Oncol. 2025;198:168-175.
    >> Share

  411. DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
    A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
    Gynecol Oncol. 2025;198:161-167.
    >> Share

  412. VINTZILEOS W, Beer H, Sunkara Y, Pruszynski J, et al
    Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.
    Gynecol Oncol. 2025;198:154-160.
    >> Share

  413. BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
    Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
    Gynecol Oncol. 2025;198:130-136.
    >> Share

  414. MATSUO K, Friedman EL, Lee MW, Masjedi AD, et al
    Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
    Gynecol Oncol. 2025;198:146-153.
    >> Share

  415. NGUYEN JMV, Zigras T, Gayowsky A, Marcucci M, et al
    Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.
    Gynecol Oncol. 2025;198:137-145.
    >> Share

  416. FU Z, Borho L, Taylor SE, Kelemen LE, et al
    Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
    Gynecol Oncol. 2025;198:112-129.
    >> Share

  417. MELO V, Vanegas G, O'Riordan DL, Kuruvilla P, et al
    A population health approach to assessing for and addressing palliative care needs in outpatients with advanced gynecologic malignancies.
    Gynecol Oncol. 2025;198:104-111.
    >> Share

  418. INIESTA MD, Ramirez PT, Munsell MF, Basabe S, et al
    Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial.
    Gynecol Oncol. 2025;198:96-103.
    >> Share

  419. RING KL, Mills AM, Howitt BE, Grisham RN, et al
    Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
    Gynecol Oncol. 2025;197:57-65.
    >> Share

  420. KURNIT KC
    The search for new therapeutic options for uterine carcinosarcoma.
    Gynecol Oncol. 2025;197:A1-A2.
    >> Share

    May 2025
  421. KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
    The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
    Gynecol Oncol. 2025;198:90-95.
    >> Share

  422. CHO WK, Park W, Kim SW, Lee KK, et al
    Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
    Gynecol Oncol. 2025;198:84-89.
    >> Share

  423. PHAM ENB, van den Berg CB, Kokke NCCJ, van Marion R, et al
    Molecular diversity in uterine carcinosarcoma: Beyond TP53.
    Gynecol Oncol. 2025;198:75-83.
    >> Share

  424. IIDA Y, Churchman M, Hollis RL, Taylor S, et al
    Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
    Gynecol Oncol. 2025;198:66-74.
    >> Share

  425. LAM C, Zhou Q, Aghajanian C, Abu-Rustum NR, et al
    Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis.
    Gynecol Oncol. 2025;198:59-65.
    >> Share

  426. EHIMIAGHE E, Marjon N, Post MD, Corr BR, et al
    The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective.
    Gynecol Oncol. 2025;198:55-58.
    >> Share

  427. ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
    Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
    Gynecol Oncol. 2025;198:49-54.
    >> Share

  428. NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
    Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
    Gynecol Oncol. 2025;198:42-48.
    >> Share

  429. YANG W, Shen Y, Tian Y, Xiao X, et al
    Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cancer.
    Gynecol Oncol. 2025;198:33-41.
    >> Share

  430. LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
    AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
    Gynecol Oncol. 2025;198:25-32.
    >> Share

  431. GU J, Zheng W, Li F, Luo C, et al
    Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
    Gynecol Oncol. 2025;198:17-24.
    >> Share

  432. BERG HF, Trovik J, Hjelmeland ME, Lien HE, et al
    Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining.
    Gynecol Oncol. 2025;198:9-16.
    >> Share

  433. LEE EK, Xiong N, Krasner C, Polak M, et al
    Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
    Gynecol Oncol. 2025;198:1-8.
    >> Share

  434. WAGAR MK, Reetz E, Huang D, Kao MJ, et al
    Patterns of primary metastasis and recurrence in mismatch repair deficiency and p53 abnormal endometrial carcinoma.
    Gynecol Oncol. 2025;197:171-178.
    >> Share

  435. WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al
    Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
    Gynecol Oncol. 2025;197:163-170.
    >> Share

  436. BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al
    Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology.
    Gynecol Oncol. 2025;197:155-162.
    >> Share

  437. XIAO Y, Pang J, Zhou Y, Lu J, et al
    FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates.
    Gynecol Oncol. 2025;197:146-154.
    >> Share

  438. EVANS E, Dholakia J, Abraham J, Hinton A, et al
    Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
    Gynecol Oncol. 2025;197:139-145.
    >> Share

  439. MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al
    TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
    Gynecol Oncol. 2025;197:129-138.
    >> Share

  440. KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
    Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
    Gynecol Oncol. 2025;197:121-128.
    >> Share

  441. KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
    Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
    Gynecol Oncol. 2025;197:116-120.
    >> Share

  442. ETTORRE VM, Bellone S, Greenman M, McNamara B, et al
    A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
    Gynecol Oncol. 2025;197:110-115.
    >> Share

  443. SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
    Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
    Gynecol Oncol. 2025;197:102-109.
    >> Share

  444. THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
    OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
    Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
    >> Share

  445. ALIMENA S, Reid H, Bercow A, Feltmate C, et al
    Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
    Gynecol Oncol. 2025;196:175-181.
    >> Share

  446. CORNEL KMC, Mehta MP, Swift BE, Covens A, et al
    The use of indocyanine green (ICG) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2025;196:146-151.
    >> Share

  447. STUEBS FA, Knoll A, Hartmann A, Matek C, et al
    Trop2-expression in primary vulvar squamous cell carcinoma.
    Gynecol Oncol. 2025;196:78-84.
    >> Share

    April 2025
  448. LOUKOVAARA M, Pasanen A, Butzow R
    Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
    Gynecol Oncol. 2025;197:96-101.
    >> Share

  449. BAE J, Kim U, Paik ES, Lim MC, et al
    Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
    Gynecol Oncol. 2025;197:91-95.
    >> Share

  450. JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al
    Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.
    Gynecol Oncol. 2025;197:83-90.
    >> Share

  451. POVEDA A, Lheureux S, Colombo N, Cibula D, et al
    Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
    Gynecol Oncol. 2025;197:74-82.
    >> Share

  452. YOU B, Anderson C, Cecere SC, Carrot A, et al
    Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
    Gynecol Oncol. 2025;197:66-73.
    >> Share

  453. FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al
    A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
    Gynecol Oncol. 2025;197:51-56.
    >> Share

  454. LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al
    Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.
    Gynecol Oncol. 2025;197:43-50.
    >> Share

  455. XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
    Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
    Gynecol Oncol. 2025;197:34-42.
    >> Share

  456. FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
    Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
    Gynecol Oncol. 2025;196:182-191.
    >> Share

  457. GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al
    Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer.
    Gynecol Oncol. 2025;197:19-24.
    >> Share

  458. WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
    Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2025;197:11-18.
    >> Share

  459. RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al
    TP53 somatic evolution in the normal endometrium of Black and White individuals.
    Gynecol Oncol. 2025;197:1-10.
    >> Share

  460. MORRIS DH, Kosmacki A, Tolby L, Marx C, et al
    Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.
    Gynecol Oncol. 2025;196:168-174.
    >> Share

  461. BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
    Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
    Gynecol Oncol. 2025;196:160-167.
    >> Share

  462. RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
    Hysterectomy or not for borderline ovarian tumor in menopause?
    Gynecol Oncol. 2025;196:152-159.
    >> Share

  463. ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
    The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
    Gynecol Oncol. 2025;196:137-145.
    >> Share

  464. METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
    Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
    Gynecol Oncol. 2025;196:129-136.
    >> Share

  465. HABLASE R, Steinke J, Aslam A, Jose R, et al
    Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
    Gynecol Oncol. 2025;196:121-128.
    >> Share

  466. GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
    ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
    Gynecol Oncol. 2025;196:113-120.
    >> Share

  467. COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al
    Exploring endometrial cancer risk stratification by copy number assessment.
    Gynecol Oncol. 2025;196:99-106.
    >> Share

  468. KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
    Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2025;196:107-112.
    >> Share

  469. VARGIU V, Santullo F, Scambia G, Naldini A, et al
    STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
    Gynecol Oncol. 2025;196:92-98.
    >> Share

  470. BUJNAK AC, Greenberg D, Chang J, Tseng J, et al
    Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes.
    Gynecol Oncol. 2025;196:85-91.
    >> Share

  471. WOLF B, Trantaki DS, Horn LC, Aktas B, et al
    Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
    Gynecol Oncol. 2025;196:69-77.
    >> Share

  472. WESTRICK AC, Bailey Z, Schlumbrecht M
    Influence of residential segregation and health provider density on advanced stage endometrial cancer diagnoses.
    Gynecol Oncol. 2025;196:62-68.
    >> Share

  473. HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
    MUTYH: Possibly another important gene in ovarian cancer?

    Gynecol Oncol. 2025;196:59-61.
    >> Share

  474. CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al
    Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: A MITO-9 retrospective study.
    Gynecol Oncol. 2025;196:54-58.
    >> Share

  475. CHAM S, Kumar A, Walter LC, Lichtman S, et al
    Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.
    Gynecol Oncol. 2025;196:42-53.
    >> Share

  476. TA QD, Do C, Sharma K, Sorooshian HZ, et al
    Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
    Gynecol Oncol. 2025;196:36-41.
    >> Share

  477. LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
    Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
    Gynecol Oncol. 2025;195:122-133.
    >> Share

  478. BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
    Signal transduction pathway activity in adult-type granulosa cell tumor samples.
    Gynecol Oncol. 2025;195:6-11.
    >> Share

  479. PODDER V, Slomovitz BM
    Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.
    Gynecol Oncol. 2025;195:A1-A2.
    >> Share

    March 2025
  480. LORUSSO D, Oaknin A, Borges GS, Damian F, et al
    Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
    Gynecol Oncol. 2025;196:28-35.
    >> Share

  481. XIE H, Sun L, Yao S, Tian X, et al
    Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
    Gynecol Oncol. 2025;196:16-27.
    >> Share

  482. KIM J, Jang J, Lim MC, Kim MH, et al
    Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
    Gynecol Oncol. 2025;196:10-15.
    >> Share

  483. MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
    ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
    Gynecol Oncol. 2025;195:192-199.
    >> Share

  484. BUJNAK AC, Solaru SA, Tewari K
    Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
    Gynecol Oncol. 2025;195:180-191.
    >> Share

  485. ETHIER JL, Shephard C, Granados DP, Dutta N, et al
    Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
    Gynecol Oncol. 2025;196:1-9.
    >> Share

  486. JOHANNET P, Flint M, Chui MH, Konner J, et al
    Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
    Gynecol Oncol. 2025;195:173-179.
    >> Share

  487. LI Y, Wu M, Liu Q, Huang C, et al
    Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
    Gynecol Oncol. 2025;195:165-172.
    >> Share

  488. LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al
    Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
    Gynecol Oncol. 2025;195:152-164.
    >> Share

  489. DEMARI JA, Glassman D, Smith S, Darby JP, et al
    Endometrial cancer somatic testing practice patterns among gynecologic oncologists.
    Gynecol Oncol. 2025;195:149-151.
    >> Share

  490. SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
    Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
    Gynecol Oncol. 2025;195:144-148.
    >> Share

  491. DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
    Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
    Gynecol Oncol. 2025;195:134-143.
    >> Share

  492. CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
    Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
    Gynecol Oncol. 2025;195:106-114.
    >> Share

  493. SALINARO J, Singh K, Sands N, Gill V, et al
    Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
    Gynecol Oncol. 2025;195:115-121.
    >> Share

  494. ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al
    Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study.
    Gynecol Oncol. 2025;195:82-88.
    >> Share

  495. LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al
    Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.
    Gynecol Oncol. 2025;195:98-105.
    >> Share

  496. ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al
    The genomic landscape of distant metastatic endometrial cancer.
    Gynecol Oncol. 2025;195:89-97.
    >> Share

  497. TYAN K, Liu KX, Smart AC, Feltmate CM, et al
    Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
    Gynecol Oncol. 2025;195:75-81.
    >> Share

  498. CARTER J, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:50-58.
    >> Share

  499. BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al
    A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
    Gynecol Oncol. 2025;195:66-74.
    >> Share

  500. COVENS A, Huang HQ, Monk BJ, Kim YB, et al
    Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
    Gynecol Oncol. 2025;195:59-65.
    >> Share

  501. LA TORRE F, Hurni Y, Farsi E, Nardi E, et al
    Adenomyosis associated with endometrial cancer: Possible correlation with pathological, immunohistochemical and molecular characteristics.
    Gynecol Oncol. 2025;195:45-49.
    >> Share

  502. LI X, Wang Z, Man X, Dai X, et al
    Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
    Gynecol Oncol. 2025;195:34-44.
    >> Share

  503. HICKS A, Borho L, Elishaev E, Berger J, et al
    All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
    Gynecol Oncol. 2025;195:26-33.
    >> Share

  504. MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
    Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
    Gynecol Oncol. 2025;195:16-25.
    >> Share

  505. FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al
    WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy.
    Gynecol Oncol. 2025;195:12-15.
    >> Share

  506. DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al
    Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
    Gynecol Oncol. 2025;194:153-158.
    >> Share

  507. HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
    An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
    Gynecol Oncol. 2025;194:145-152.
    >> Share

  508. WENZEL L, McKinney C, Jensen S, Peipert D, et al
    Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).
    Gynecol Oncol. 2025;194:137-144.
    >> Share

  509. VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
    Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
    Gynecol Oncol. 2025;194:131-136.
    >> Share

  510. LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
    An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
    Gynecol Oncol. 2025;194:125-130.
    >> Share

  511. DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al
    Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists.
    Gynecol Oncol. 2025;194:119-124.
    >> Share

  512. VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al
    Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups.
    Gynecol Oncol. 2025;194:86-90.
    >> Share

  513. ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
    Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
    Gynecol Oncol. 2025;194:1-10.
    >> Share

  514. ESKANDER RN
    Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
    Gynecol Oncol. 2025;194:A3-A4.
    >> Share

    February 2025
  515. WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
    Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;195:1-5.
    >> Share

  516. ASARE A, Previs RA, Spinosa D, Fellman B, et al
    Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
    Gynecol Oncol. 2025;194:112-118.
    >> Share

  517. HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al
    Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
    Gynecol Oncol. 2025;194:98-104.
    >> Share

  518. NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al
    Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals.
    Gynecol Oncol. 2025;194:105-111.
    >> Share

  519. MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
    Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
    Gynecol Oncol. 2025;194:91-97.
    >> Share

  520. HAIGHT P, Bilbe C, Riedinger C, Backes F, et al
    Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
    Gynecol Oncol. 2025;194:80-85.
    >> Share

  521. ALVERO AB, Wu S, Farrell A, Kim S, et al
    Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
    Gynecol Oncol. 2025;194:71-79.
    >> Share

  522. SUN H, Huo X, Bi X, Cao D, et al
    Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
    Gynecol Oncol. 2025;194:60-70.
    >> Share

  523. MATSUO K, Agarwal J, Chen L, Furey KB, et al
    Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
    Gynecol Oncol. 2025;194:51-59.
    >> Share

  524. TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al
    Impact of telehealth legislation on gynecologic oncology services: Policy updates.
    Gynecol Oncol. 2025;194:48-50.
    >> Share

  525. GAILLARD S, Verma N, Berg M, Harrison J, et al
    A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2025;194:41-47.
    >> Share

  526. CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
    HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
    Gynecol Oncol. 2025;194:33-40.
    >> Share

  527. KIM J, Park SY, Kim JH, Lee SW, et al
    Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
    Gynecol Oncol. 2025;194:25-32.
    >> Share

  528. ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
    Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
    Gynecol Oncol. 2025;194:18-24.
    >> Share

  529. VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
    Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
    Gynecol Oncol. 2025;194:11-17.
    >> Share

  530. CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
    High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
    Gynecol Oncol. 2025;193:148-155.
    >> Share

  531. STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al
    PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
    Gynecol Oncol. 2025;193:98-104.
    >> Share

  532. HOROWITZ NS, St Laurent JD, Berkowitz RS
    Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
    Gynecol Oncol. 2025;193:A1-A2.
    >> Share

    January 2025
  533. MAKI PM, Rubin LH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2025;193:141-147.
    >> Share

  534. KIM YJ, Lee J, Park S, Kim YM, et al
    The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
    Gynecol Oncol. 2025;193:136-140.
    >> Share

  535. CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
    Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
    Gynecol Oncol. 2025;193:119-129.
    >> Share

  536. O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
    Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
    Gynecol Oncol. 2025;193:130-135.
    >> Share

  537. TOBONI MD, Dinkins K, Wu S, Mattox T, et al
    Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
    Gynecol Oncol. 2025;193:89-97.
    >> Share

  538. SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
    Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
    Gynecol Oncol. 2025;193:113-118.
    >> Share

  539. UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
    Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
    Gynecol Oncol. 2025;193:105-112.
    >> Share

  540. DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
    Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
    Gynecol Oncol. 2025;193:81-88.
    >> Share

  541. WANG H, Zhu J, Zou D, Rao Q, et al
    Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
    Gynecol Oncol. 2025;193:58-64.
    >> Share

  542. AHMED J, Stephen B, Khawaja MR, Yang Y, et al
    A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2025;193:73-80.
    >> Share

  543. MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
    Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
    Gynecol Oncol. 2025;193:65-72.
    >> Share

  544. LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
    Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
    Gynecol Oncol. 2025;193:41-48.
    >> Share

  545. RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
    Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:49-57.
    >> Share

  546. BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
    Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
    Gynecol Oncol. 2025;193:30-40.
    >> Share

  547. WALKER AR, Leite S, Taylor N, Graul A, et al
    Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2025;193:24-29.
    >> Share

  548. SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
    Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
    Gynecol Oncol. 2025;193:12-19.
    >> Share

  549. VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
    Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
    Gynecol Oncol. 2025;192:163-170.
    >> Share

  550. MARINO G, Marchetta L, Negri S, Testa F, et al
    Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
    Gynecol Oncol. 2025;192:89-93.
    >> Share

    December 2024
  551. NEILSON A, Jamieson A, Chiu D, Leung S, et al
    Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
    Gynecol Oncol. 2024;193:1-11.
    >> Share

  552. MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
    Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
    Gynecol Oncol. 2024;192:181-188.
    >> Share

  553. VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
    Less is more: The benefits of reduced follow-up in gynecologic cancers.
    Gynecol Oncol. 2024;192:178-180.
    >> Share

  554. LIU YL, Praiss AM, Chiang S, Devereaux K, et al
    Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
    Gynecol Oncol. 2024;192:171-177.
    >> Share

  555. KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
    Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
    Gynecol Oncol. 2024;192:155-162.
    >> Share

  556. AZAIS H, Brochard C, Taly V, Benoit L, et al
    Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
    Gynecol Oncol. 2024;192:145-154.
    >> Share

  557. NGUYEN T, Yi Y, Morron S, Brittain D, et al
    Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
    Gynecol Oncol. 2024;192:137-144.
    >> Share

  558. MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
    Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
    Gynecol Oncol. 2024;192:128-136.
    >> Share

  559. GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
    Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
    Gynecol Oncol. 2024;192:120-127.
    >> Share

  560. CASTELLANO T, Lara OD, McCormick C, Chase D, et al
    Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
    Gynecol Oncol. 2024;192:111-119.
    >> Share

  561. PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
    Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecol Oncol. 2024;192:102-110.
    >> Share

  562. COLSON-FEARON D, Viswanathan AN
    Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
    Gynecol Oncol. 2024;191:228-232.
    >> Share

  563. MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
    Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
    Gynecol Oncol. 2024;191:212-218.
    >> Share

  564. FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
    Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
    Gynecol Oncol. 2024;191:106-113.
    >> Share

  565. WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
    Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
    Gynecol Oncol. 2024;191:100-105.
    >> Share

  566. THAYER EG, Manning-Geist BL
    Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:A1-A2.
    >> Share

    November 2024
  567. SHU T, Liang Y, Zhang S, Sun T, et al
    The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
    Gynecol Oncol. 2024;192:94-101.
    >> Share

  568. BORHO L, Elishaev E, Bao R, O'Brien E, et al
    Association of neighborhood social vulnerability with ovarian cancer survival.
    Gynecol Oncol. 2024;192:32-39.
    >> Share

  569. KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
    Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
    Gynecol Oncol. 2024;192:80-88.
    >> Share

  570. CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
    A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
    Gynecol Oncol. 2024;192:73-79.
    >> Share

  571. SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
    Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
    Gynecol Oncol. 2024;192:65-72.
    >> Share

  572. KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
    Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
    Gynecol Oncol. 2024;192:59-64.
    >> Share

  573. MULUGETA-GORDON L, Smith AJB
    Insurance coverage and access to gynecologic oncology: Where are we are now.
    Gynecol Oncol. 2024;192:56-58.
    >> Share

  574. FRANCIS KE, Simon S, Gebski V, Joly F, et al
    Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
    Gynecol Oncol. 2024;192:50-55.
    >> Share

  575. POWELL MA, Cibula D, O'Malley DM, Boere I, et al
    Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
    Gynecol Oncol. 2024;192:40-49.
    >> Share

  576. COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
    Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
    Gynecol Oncol. 2024;192:24-31.
    >> Share

  577. DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
    Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
    Gynecol Oncol. 2024;191:275-286.
    >> Share

  578. VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
    Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
    Gynecol Oncol. 2024;192:15-23.
    >> Share

  579. MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
    Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
    Gynecol Oncol. 2024;192:8-14.
    >> Share

  580. HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
    What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
    Gynecol Oncol. 2024;192:1-7.
    >> Share

  581. KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
    KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
    Gynecol Oncol. 2024;191:299-306.
    >> Share

  582. LEE AW, Poynor V, Siddiqui S
    Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
    Gynecol Oncol. 2024;191:292-298.
    >> Share

  583. BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
    Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
    Gynecol Oncol. 2024;191:287-291.
    >> Share

  584. JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
    Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
    Gynecol Oncol. 2024;190:272-282.
    >> Share

  585. PROPPE L, Jaeger A, Goy Y, Petersen C, et al
    Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
    Gynecol Oncol. 2024;190:264-271.
    >> Share

  586. CHOI YK, Lee JH, Kim YS, Wee CW, et al
    Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
    Gynecol Oncol. 2024;190:222-229.
    >> Share

  587. SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
    Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
    Gynecol Oncol. 2024;190:189-199.
    >> Share

  588. NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
    Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
    Gynecol Oncol. 2024;190:160-166.
    >> Share

  589. HEUS C, Stelten S, Kenter GG, Buffart LM, et al
    Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
    Gynecol Oncol. 2024;190:131-138.
    >> Share

  590. WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
    Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
    Gynecol Oncol. 2024;190:124-130.
    >> Share

  591. METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
    Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
    Gynecol Oncol. 2024;190:62-69.
    >> Share

  592. MERTEN R, Strnad V, Karius A, Lotter M, et al
    Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
    Gynecol Oncol. 2024;190:35-41.
    >> Share

  593. TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
    Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
    Gynecol Oncol. 2024;190:18-27.
    >> Share

  594. BROWN J
    Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
    Gynecol Oncol. 2024;190:A1-A2.
    >> Share

    October 2024
  595. VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
    Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
    Gynecol Oncol. 2024;191:265-274.
    >> Share

  596. HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
    Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:259-264.
    >> Share

  597. MOORE KN, Lorusso D, Oaknin A, Oza A, et al
    Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
    Gynecol Oncol. 2024;191:249-258.
    >> Share

  598. PENG S, Zheng Y, Liu J, Chen S, et al
    Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
    Gynecol Oncol. 2024;191:240-248.
    >> Share

  599. GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
    Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
    Gynecol Oncol. 2024;191:233-239.
    >> Share

  600. NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
    Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:219-227.
    >> Share

  601. LI G, Li X, Yin R, Feng M, et al
    Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
    Gynecol Oncol. 2024;191:165-171.
    >> Share

  602. HICKEY M, Trainer AH, Krejany EO, Brand A, et al
    What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
    Gynecol Oncol. 2024;191:201-211.
    >> Share

  603. HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
    Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
    Gynecol Oncol. 2024;191:194-200.
    >> Share

  604. YONEMORI K, Boni V, Min KG, Meniawy TM, et al
    Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
    Gynecol Oncol. 2024;191:172-181.
    >> Share

  605. ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
    ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
    Gynecol Oncol. 2024;191:182-193.
    >> Share

  606. PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
    Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
    Gynecol Oncol. 2024;191:158-164.
    >> Share

  607. PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
    Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
    Gynecol Oncol. 2024;191:150-157.
    >> Share

  608. OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
    Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
    Gynecol Oncol. 2024;191:124-131.
    >> Share

  609. SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
    Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
    Gynecol Oncol. 2024;191:143-149.
    >> Share

  610. PINTO P, Moro F, Alcazar JL, Alessi S, et al
    Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
    Gynecol Oncol. 2024;191:132-142.
    >> Share

  611. KONG W, Deng B, Shen X, John C, et al
    Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
    Gynecol Oncol. 2024;191:116-123.
    >> Share

  612. NG ZY, Manchanda R, Lopez A, Obermair A, et al
    The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
    Gynecol Oncol. 2024;191:95-99.
    >> Share

  613. CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
    Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
    Gynecol Oncol. 2024;191:86-94.
    >> Share

  614. RUSHTON T, Krause HB, Samec T, Elliott A, et al
    Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;191:80-85.
    >> Share

  615. LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
    Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
    Gynecol Oncol. 2024;191:74-79.
    >> Share

  616. BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
    Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
    Gynecol Oncol. 2024;191:67-73.
    >> Share

  617. VAZ J, Piver R, Brzezinska B, Suhner J, et al
    Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
    Gynecol Oncol. 2024;189:129-136.
    >> Share

    September 2024
  618. WAN S, Gao Y, Wu S, Wang H, et al
    Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
    Gynecol Oncol. 2024;191:56-66.
    >> Share

  619. LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
    Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
    Gynecol Oncol. 2024;191:45-55.
    >> Share

  620. PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
    Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
    Gynecol Oncol. 2024;191:37-44.
    >> Share

  621. YANG X, Li C, Li Z, Du D, et al
    The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
    Gynecol Oncol. 2024;191:31-36.
    >> Share

  622. LI X, Argenta PA, Brown K, Honeyfield K, et al
    Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
    Gynecol Oncol. 2024;191:25-30.
    >> Share

  623. JANG EB, Lee AJ, So KA, Lee SJ, et al
    Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
    Gynecol Oncol. 2024;191:19-24.
    >> Share

  624. ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
    Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;191:10-18.
    >> Share

  625. NIEF CA, Long SE, McCleary TL, Kidd E, et al
    Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
    Gynecol Oncol. 2024;190:298-306.
    >> Share

  626. MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
    Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
    Gynecol Oncol. 2024;191:1-9.
    >> Share

  627. FULLERTON R, Martell K, Khanolkar R, Phan T, et al
    Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
    Gynecol Oncol. 2024;190:291-297.
    >> Share

  628. BROWN J, Miller A, Holman LL, Backes F, et al
    Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
    Gynecol Oncol. 2024;190:283-290.
    >> Share

  629. NAHSHON C, Leitao MM Jr, Segev Y
    Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
    Gynecol Oncol. 2024;190:262-263.
    >> Share

  630. ADJEI NN, Haas A, Zhao H, Primm KM, et al
    Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
    Gynecol Oncol. 2024;190:255-261.
    >> Share

  631. NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
    Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
    Gynecol Oncol. 2024;190:243-249.
    >> Share

  632. RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
    Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
    Gynecol Oncol. 2024;190:236-242.
    >> Share

  633. MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
    Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2024;190:230-235.
    >> Share

  634. YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
    Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
    Gynecol Oncol. 2024;190:215-221.
    >> Share

  635. POTHURI B, Sawaged Z, Karpel HC, Li X, et al
    A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
    Gynecol Oncol. 2024;190:209-214.
    >> Share

  636. PIFER PM, Kilar CR, Beriwal S
    Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
    Gynecol Oncol. 2024;188:A1-A3.
    >> Share

  637. WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
    Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
    Gynecol Oncol. 2024;188:125-130.
    >> Share

  638. WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
    A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
    Gynecol Oncol. 2024;188:120-124.
    >> Share

  639. MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
    Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
    Gynecol Oncol. 2024;188:81-82.
    >> Share

  640. LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
    Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;188:71-80.
    >> Share

  641. WILHITE AM, Wu S, Xiu J, Gibney GT, et al
    A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
    Gynecol Oncol. 2024;188:13-21.
    >> Share

  642. POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
    Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
    Gynecol Oncol. 2024;188:1-7.
    >> Share

    August 2024
  643. LIM H, Kim SI, Kim MK, Yoon SH, et al
    Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
    Gynecol Oncol. 2024;190:200-208.
    >> Share

  644. MILLER EA, Chowdhary B, Chapman-Davis E
    Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
    Gynecol Oncol. 2024;190:186-188.
    >> Share

  645. MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
    Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
    Gynecol Oncol. 2024;190:146-152.
    >> Share

  646. FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
    Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
    Gynecol Oncol. 2024;190:179-185.
    >> Share

  647. QI C, Lyu M, Yao Z, Zhang F, et al
    SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
    Gynecol Oncol. 2024;190:167-178.
    >> Share

  648. CHUK E, Conway JL, Hanuschak J, Han K, et al
    Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
    Gynecol Oncol. 2024;190:153-159.
    >> Share

  649. KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
    Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
    Gynecol Oncol. 2024;190:139-145.
    >> Share

  650. BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
    The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
    Gynecol Oncol. 2024;190:119-123.
    >> Share

  651. YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
    Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
    Gynecol Oncol. 2024;190:113-118.
    >> Share

  652. SKOF E, Stegel V, Dragos VS, Blatnik A, et al
    Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
    Gynecol Oncol. 2024;190:104-112.
    >> Share

  653. LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
    Quality of life and survivorship in patients with low-grade ovarian cancer.
    Gynecol Oncol. 2024;190:96-103.
    >> Share

  654. KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
    Incidence of endometrial cancer in BRCA mutation carriers.
    Gynecol Oncol. 2024;189:148-155.
    >> Share

  655. WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
    Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
    Gynecol Oncol. 2024;190:90-95.
    >> Share

  656. GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
    The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
    Gynecol Oncol. 2024;190:84-89.
    >> Share

  657. SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
    Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
    Gynecol Oncol. 2024;190:78-83.
    >> Share

  658. GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
    Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
    Gynecol Oncol. 2024;190:70-77.
    >> Share

  659. ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
    Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
    Gynecol Oncol. 2024;190:53-61.
    >> Share

  660. YOKOI A, Machida H, Shimada M, Mastuo K, et al
    Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;190:42-52.
    >> Share

  661. GU Y, Liu Y, Cheng H, Wang W, et al
    Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
    Gynecol Oncol. 2024;190:28-34.
    >> Share

  662. CUN HT, Bernard L, Lande KT, Lawson BC, et al
    Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
    Gynecol Oncol. 2024;189:138-145.
    >> Share

  663. FROEDING LP, Jensen PT
    Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
    Gynecol Oncol. 2024;189:137.
    >> Share

  664. OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
    Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
    Gynecol Oncol. 2024;190:11-17.
    >> Share

  665. RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
    Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
    Gynecol Oncol. 2024;190:1-10.
    >> Share

  666. HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
    Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
    Gynecol Oncol. 2024;189:125-128.
    >> Share

  667. CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
    Implementation of a financial navigation program in gynecologic oncology.
    Gynecol Oncol. 2024;189:119-124.
    >> Share

  668. VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
    Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
    Gynecol Oncol. 2024;189:111-118.
    >> Share

  669. GLASER S, Han E
    Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
    Gynecol Oncol. 2024;187:A1-A2.
    >> Share

  670. STROOT IAS, Bart J, Hollema H, Jalving M, et al
    Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
    Gynecol Oncol. 2024;187:198-203.
    >> Share

  671. WAGAR MK, Naik A, Zhang RC, Godecker A, et al
    Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
    Gynecol Oncol. 2024;187:192-197.
    >> Share

  672. DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
    Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
    Gynecol Oncol. 2024;187:145-150.
    >> Share

  673. VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
    Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    Gynecol Oncol. 2024;187:113-119.
    >> Share

  674. ADOLPH L, Mann A, Liu XQ, Roberts L, et al
    Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
    Gynecol Oncol. 2024;187:74-79.
    >> Share

  675. VUE NC, Sassani J, Prairie B, Yin Y, et al
    Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
    Gynecol Oncol. 2024;187:58-63.
    >> Share

  676. SWIFT BE, Khoja L, Matthews J, Croke J, et al
    Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
    Gynecol Oncol. 2024;187:46-50.
    >> Share

    July 2024
  677. DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
    Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
    Gynecol Oncol. 2024;189:109-110.
    >> Share

  678. JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
    Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
    Gynecol Oncol. 2024;189:101-108.
    >> Share

  679. ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
    Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
    Gynecol Oncol. 2024;189:98-100.
    >> Share

  680. GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
    Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
    Gynecol Oncol. 2024;189:90-97.
    >> Share

  681. SULLIVAN MW, Kanbergs AN, Growdon WB
    Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
    Gynecol Oncol. 2024;189:88-89.
    >> Share

  682. HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
    Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
    Gynecol Oncol. 2024;189:80-87.
    >> Share

  683. FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
    ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;189:75-79.
    >> Share

  684. LEE YW, Wang V, Wang MJ, Kim KH, et al
    The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
    Gynecol Oncol. 2024;189:64-67.
    >> Share

  685. KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
    Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
    Gynecol Oncol. 2024;189:68-74.
    >> Share

  686. CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
    Molecular classification improves preoperative risk assessment of endometrial cancer.
    Gynecol Oncol. 2024;189:56-63.
    >> Share

  687. BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
    Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
    Gynecol Oncol. 2024;189:49-55.
    >> Share

  688. SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
    Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
    Gynecol Oncol. 2024;189:41-48.
    >> Share

  689. POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
    Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
    Gynecol Oncol. 2024;189:37-40.
    >> Share

  690. ANDRES S, Finch L, Iasonos A, Zhou Q, et al
    Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
    Gynecol Oncol. 2024;189:30-36.
    >> Share

  691. MAHONEY DE, Mukherjee R, Thompson J
    Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
    Gynecol Oncol. 2024;189:24-29.
    >> Share

  692. MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
    Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    Gynecol Oncol. 2024;189:16-23.
    >> Share

  693. ARO K, Pasanen A, Butzow R, Loukovaara M, et al
    The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
    Gynecol Oncol. 2024;189:9-15.
    >> Share

  694. GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
    A toolkit for a modern gynecologic oncology tissue bank.
    Gynecol Oncol. 2024;189:1-8.
    >> Share

  695. EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
    Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
    Gynecol Oncol. 2024;188:169-183.
    >> Share

  696. KUMAR PP, Smith D, Key J, Dong H, et al
    Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
    Gynecol Oncol. 2024;188:162-168.
    >> Share

  697. SHALOWITZ DI, Rajczi A
    Refining research on access to gynecologic cancer care: The DIMeS framework.
    Gynecol Oncol. 2024;188:158-161.
    >> Share

  698. CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
    Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
    Gynecol Oncol. 2024;188:147-157.
    >> Share

  699. NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
    Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
    Gynecol Oncol. 2024;188:140-146.
    >> Share

  700. STEWART KT, Jafari H, Pattillo J, Santos J, et al
    Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
    Gynecol Oncol. 2024;188:131-139.
    >> Share

  701. RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
    Gynecol Oncol. 2024;186:110-116.
    >> Share

    June 2024
  702. FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
    Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
    Gynecol Oncol. 2024;188:97-102.
    >> Share

  703. MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
    Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
    Gynecol Oncol. 2024;188:111-119.
    >> Share

  704. MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
    NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
    Gynecol Oncol. 2024;188:103-110.
    >> Share

  705. KA K, Cordoba A, Cagetti LV, Schiappa R, et al
    Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
    Gynecol Oncol. 2024;188:90-96.
    >> Share

  706. KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
    Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
    Gynecol Oncol. 2024;188:83-89.
    >> Share

  707. MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
    Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
    Gynecol Oncol. 2024;188:52-57.
    >> Share

  708. KOH B, Ryu JY, Noh JJ, Hwang JR, et al
    Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
    Gynecol Oncol. 2024;188:60-70.
    >> Share

  709. EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
    Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
    Gynecol Oncol. 2024;188:58-59.
    >> Share

  710. BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
    The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
    Gynecol Oncol. 2024;188:44-51.
    >> Share

  711. GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
    Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
    Gynecol Oncol. 2024;188:35-43.
    >> Share

  712. CHEN H, Chen Y, Zheng A, Tan X, et al
    Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
    Gynecol Oncol. 2024;188:27-34.
    >> Share

  713. WALKER CA, Edwards C, McIntire D, Makepeace L, et al
    Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
    Gynecol Oncol. 2024;188:22-26.
    >> Share

  714. PATEL KB, Escamilla V, Wolfe L, Morris T, et al
    Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
    Gynecol Oncol. 2024;188:8-12.
    >> Share

  715. FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
    Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
    Gynecol Oncol. 2024;186:211-215.
    >> Share

  716. BORHO L, Bao R, Elishaev E, Dinkins KD, et al
    Association of allostatic load with overall survival in epithelial ovarian cancer.
    Gynecol Oncol. 2024;186:204-210.
    >> Share

  717. CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
    Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
    Gynecol Oncol. 2024;187:249-252.
    >> Share

  718. MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
    Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
    Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
    >> Share

  719. AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
    Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Gynecol Oncol. 2024;187:241-248.
    >> Share

  720. VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
    Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Gynecol Oncol. 2024;187:128-138.
    >> Share

  721. O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
    Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
    Gynecol Oncol. 2024;186:199-203.
    >> Share

  722. BERTON D, Pautier P, Lorusso D, Gennigens C, et al
    Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
    Gynecol Oncol. 2024;186:191-198.
    >> Share

  723. CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
    Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
    Gynecol Oncol. 2024;185:165-172.
    >> Share

  724. SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
    A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
    Gynecol Oncol. 2024;185:83-94.
    >> Share

  725. FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
    Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
    Gynecol Oncol. 2024;185:58-67.
    >> Share

  726. HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
    High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
    Gynecol Oncol. 2024;185:17-24.
    >> Share

    May 2024
  727. FRANCO S, Godley LA
    Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
    Gynecol Oncol. 2024;187:235-240.
    >> Share

  728. LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
    Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
    Gynecol Oncol. 2024;187:227-234.
    >> Share

  729. PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
    Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
    Gynecol Oncol. 2024;187:221-226.
    >> Share

  730. YUAN G, Zhang K, Zheng H, Wu Y, et al
    Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
    Gynecol Oncol. 2024;187:212-220.
    >> Share

  731. CARBALLO EV, Kim KH, Penn CA
    Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
    Gynecol Oncol. 2024;187:204-211.
    >> Share

  732. OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
    ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
    Gynecol Oncol. 2024;187:184-191.
    >> Share

  733. PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
    A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
    Gynecol Oncol. 2024;187:178-183.
    >> Share

  734. MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
    Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
    Gynecol Oncol. 2024;187:170-177.
    >> Share

  735. LARAJA A, Connor Y, Poulson MR
    The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
    Gynecol Oncol. 2024;187:163-169.
    >> Share

  736. FERRIS JS, Prest MT, Hur C, Chen L, et al
    Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
    Gynecol Oncol. 2024;187:151-162.
    >> Share

  737. ZENATRI M, Perennec T, Michon C, Gernier F, et al
    Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
    Gynecol Oncol. 2024;187:139-144.
    >> Share

  738. HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
    A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
    Gynecol Oncol. 2024;187:120-127.
    >> Share

  739. LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
    A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
    Gynecol Oncol. 2024;187:105-112.
    >> Share

  740. ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
    Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
    Gynecol Oncol. 2024;187:98-104.
    >> Share

  741. PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
    Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Gynecol Oncol. 2024;187:92-97.
    >> Share

  742. KIM JH, Han KH, Park EY, Kim ET, et al
    Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2024;187:85-91.
    >> Share

  743. FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
    Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
    Gynecol Oncol. 2024;187:80-84.
    >> Share

  744. LIANG S, Ge H, Zhou S, Tang J, et al
    Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
    Gynecol Oncol. 2024;187:64-73.
    >> Share

  745. CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
    Trop-2 expression and the tumor immune microenvironment in cervical cancer.
    Gynecol Oncol. 2024;187:51-57.
    >> Share

  746. GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
    Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
    Gynecol Oncol. 2024;186:182-190.
    >> Share

  747. MATSUO K, Chen L, Klar M, Lee MW, et al
    Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
    Gynecol Oncol. 2024;187:37-45.
    >> Share

  748. MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
    Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
    Gynecol Oncol. 2024;187:30-36.
    >> Share

  749. PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
    Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
    Gynecol Oncol. 2024;187:21-29.
    >> Share

  750. DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
    Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
    Gynecol Oncol. 2024;187:12-20.
    >> Share

  751. RING KL, Duska LR
    How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
    Gynecol Oncol. 2024;184:8-15.
    >> Share

  752. MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
    Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
    Gynecol Oncol. 2024;184:16-23.
    >> Share

    April 2024
  753. HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
    Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
    Gynecol Oncol. 2024;186:176-181.
    >> Share

  754. JIANG Z, Zhu M, Zhang L, Cui H, et al
    Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
    Gynecol Oncol. 2024;187:1-11.
    >> Share

  755. HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
    Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
    Gynecol Oncol. 2024;184:254-258.
    >> Share

  756. SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
    "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
    Gynecol Oncol. 2024;186:170-175.
    >> Share

  757. CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
    Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Gynecol Oncol. 2024;186:161-169.
    >> Share

  758. PENG H, Jiang J, Li L, Hao Z, et al
    Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
    Gynecol Oncol. 2024;186:154-160.
    >> Share

  759. ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
    Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Gynecol Oncol. 2024;186:144-153.
    >> Share

  760. PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
    ChatGPT accurately performs genetic counseling for gynecologic cancers.
    Gynecol Oncol. 2024;183:115-119.
    >> Share

  761. WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
    The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
    Gynecol Oncol. 2024;186:137-143.
    >> Share

  762. ZHAO Z, Wang J, Kong W, Fang Z, et al
    Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
    Gynecol Oncol. 2024;186:126-136.
    >> Share

  763. NELSON AT, Harris AK, Watson D, Kamihara J, et al
    Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
    Gynecol Oncol. 2024;186:117-125.
    >> Share

  764. EHMANN S, Lam C, Zhou Q, Iasonos A, et al
    Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;186:104-109.
    >> Share

  765. ESPINOSA I, D'Angelo E, Prat J
    Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
    Gynecol Oncol. 2024;186:94-103.
    >> Share

  766. MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
    Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
    Gynecol Oncol. 2024;186:85-93.
    >> Share

  767. GITTO SB, Ihewulezi CJN, Powell DJ Jr
    Adoptive T cell therapy for ovarian cancer.
    Gynecol Oncol. 2024;186:77-84.
    >> Share

  768. DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
    Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
    Gynecol Oncol. 2024;186:69-76.
    >> Share

  769. GIEN LT, Enserro DM, Block MS, Waggoner S, et al
    Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
    Gynecol Oncol. 2024;186:61-68.
    >> Share

  770. SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
    Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
    Gynecol Oncol. 2024;186:53-60.
    >> Share

  771. KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
    Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
    Gynecol Oncol. 2024;183:103-114.
    >> Share

  772. HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
    High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:42-52.
    >> Share

  773. VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
    Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
    Gynecol Oncol. 2024;186:35-41.
    >> Share


  774. Introduction to SGO VSI.
    Gynecol Oncol. 2024;183:A7.
    >> Share

  775. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
    Gynecol Oncol. 2024;183:R1.
    >> Share

    March 2024
  776. MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
    TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
    Gynecol Oncol. 2024;186:26-34.
    >> Share

  777. SHEN X, Wang J, Deng B, Chen S, et al
    High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
    Gynecol Oncol. 2024;183:93-102.
    >> Share

  778. SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
    Delayed publication of clinical trials in gynecologic oncology.
    Gynecol Oncol. 2024;183:74-77.
    >> Share

  779. HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
    Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
    Gynecol Oncol. 2024;186:9-16.
    >> Share

  780. DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
    Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
    Gynecol Oncol. 2024;186:1-8.
    >> Share

  781. WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
    System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
    Gynecol Oncol. 2024;183:85-92.
    >> Share

  782. RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
    Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
    Gynecol Oncol. 2024;183:78-84.
    >> Share

  783. KIM NK, Choi CH, Seong SJ, Lee JM, et al
    Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
    Gynecol Oncol. 2024;183:68-73.
    >> Share

  784. PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
    Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Gynecol Oncol. 2024;183:61-67.
    >> Share

  785. LIANG MI, Dholakia JD, Lee GM, Wang L, et al
    Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
    Gynecol Oncol. 2024;183:53-60.
    >> Share

  786. AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
    Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
    Gynecol Oncol. 2024;183:47-52.
    >> Share

  787. HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
    Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
    Gynecol Oncol. 2024;183:39-46.
    >> Share

  788. LEVINE BJ
    Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
    Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
    >> Share

  789. ROSS DH, Gomez K, Harmon G, Mysz ML, et al
    Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
    Gynecol Oncol. 2024;183:33-38.
    >> Share

  790. CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
    Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
    Gynecol Oncol. 2024;183:15-24.
    >> Share

  791. BYRNE M, Sia TY, Fong C, Khurram A, et al
    Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
    Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
    >> Share

  792. GASS P, Thiel FC, Haberle L, Ackermann S, et al
    Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
    Gynecol Oncol. 2024;183:25-32.
    >> Share

  793. BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
    Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
    Gynecol Oncol. 2024;183:7-8.
    >> Share

  794. GLASER GE, Maddy B, Kumar A, Ishitani K, et al
    Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
    Gynecol Oncol. 2024;183:9-14.
    >> Share

  795. PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
    Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
    Gynecol Oncol. 2024;185:194-201.
    >> Share

  796. GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
    2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
    Gynecol Oncol. 2024;184:245-253.
    >> Share

  797. RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2024;185:186-193.
    >> Share

  798. NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
    Real world challenges and disparities in the systemic treatment of ovarian cancer.
    Gynecol Oncol. 2024;185:180-185.
    >> Share

  799. OLAWAIYE AB
    2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
    Gynecol Oncol. 2024;184:243-244.
    >> Share

  800. EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
    Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
    Gynecol Oncol. 2024;185:173-179.
    >> Share

  801. GLASER GE, Dowdy SC
    Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
    Gynecol Oncol. 2024;182:A1-A2.
    >> Share

  802. CHEN W, Xie J, Gao C, Zhang C, et al
    Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2024;182:108-114.
    >> Share

    February 2024
  803. CAO B, Li Y, Liu Y, Chen X, et al
    A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
    Gynecol Oncol. 2024;185:156-164.
    >> Share

  804. CHEN Y, Yang J, Wan Y, Li Q, et al
    DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
    Gynecol Oncol. 2024;185:148-155.
    >> Share

  805. COSTALES AB, Crane EK, Chambers L, Yao M, et al
    Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
    Gynecol Oncol. 2024;185:143-147.
    >> Share

  806. SALMAN L, Covens A, Vicus D, Podolsky S, et al
    The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
    Gynecol Oncol. 2024;185:138-142.
    >> Share

  807. RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
    Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Gynecol Oncol. 2024;185:128-137.
    >> Share

  808. AGUSTI N, Kanbergs A, Nitecki R
    Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
    Gynecol Oncol. 2024;185:121-127.
    >> Share

  809. MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
    Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
    >> Share

  810. APPLEBAUM AJ
    The importance of family-focused care in the setting of advanced gynecological cancers.
    Gynecol Oncol. 2024;181:A1-A2.
    >> Share

  811. PELTECU G
    Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
    Gynecol Oncol. 2024;181:40-45.
    >> Share

  812. VASTA FM, Cormio G, Cassani C, Bergamini A, et al
    Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
    Gynecol Oncol. 2024;181:28-32.
    >> Share

  813. TAYLOR DD, Gercel-Taylor C, Parker LP
    Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
    Gynecol Oncol. 2024;181:186.
    >> Share

    January 2024
  814. FADER AN, Ko EM, Pollock BD, Blank SV, et al
    An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
    Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
    >> Share

    October 2023
  815. KIM JH, Kim SI, Park EY, Ha HI, et al
    Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;179:24-32.
    >> Share

  816. HALL TR, MacDonald JE, Bylinowski KM, Alvarez EA, et al
    Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement.
    Gynecol Oncol. 2023;177:180-185.
    >> Share

  817. HUI C, Mendoza MG, von Eyben R, Dorigo O, et al
    Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
    Gynecol Oncol. 2023;177:150-156.
    >> Share

  818. TOBONI MD, Wu S, Farrell A, Xiu J, et al
    Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.
    Gynecol Oncol. 2023;177:132-141.
    >> Share

  819. LIM H, Ju Y, Kim SI, Park JH, et al
    Clinical implications of histologic subtypes on survival outcomes in primary mucinous ovarian carcinoma.
    Gynecol Oncol. 2023;177:117-124.
    >> Share

  820. SPAGNOL G, Marchetti M, De Tommasi O, Vitagliano A, et al
    Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors.
    Gynecol Oncol. 2023;177:109-116.
    >> Share

  821. SAAB RH, Salvo G, Gonzales NR, Munsell MF, et al
    Social media use is associated with higher levels of anxiety and depression in patients with neuroendocrine carcinoma of the cervix: A NeCTuR study.
    Gynecol Oncol. 2023;177:95-102.
    >> Share

  822. NASIOUDIS D, Fernandez ML, Wong N, Powell DJ Jr, et al
    The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
    Gynecol Oncol. 2023;177:86-94.
    >> Share

  823. MORTON M, McLaughlin EM, Calo CA, Lightfoot M, et al
    Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?
    Gynecol Oncol. 2023;177:46-52.
    >> Share

  824. NASIOUDIS D, Latif NA, Ko EM, Cory L, et al
    Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.
    Gynecol Oncol. 2023;177:14-19.
    >> Share

  825. LEE MW, Vallejo A, Mandelbaum RS, Yessaian AA, et al
    Temporal trends of failure-to-rescue following perioperative complications in vulvar cancer surgery in the United States.
    Gynecol Oncol. 2023;177:1-8.
    >> Share

    September 2023
  826. MARSH LA, Kim TH, Zhang M, Kubalanza K, et al
    Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival.
    Gynecol Oncol. 2023;177:173-179.
    >> Share

  827. AGUSTI N, Viveros-Carreno D, Mora-Soto N, Ramirez PT, et al
    Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:157-164.
    >> Share

  828. LEE HC, Jeong JW, Lee JH, Kim SH, et al
    High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial.
    Gynecol Oncol. 2023;177:142-149.
    >> Share

    August 2023
  829. NARAYAN P, Ahsan MD, Webster EM, Perez L, et al
    Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2023;177:72-85.
    >> Share

  830. AO W, Kim HI, Tommarello D, Conrads KA, et al
    Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatment.
    Gynecol Oncol. 2023;177:60-71.
    >> Share

  831. MARJON N, Guerra R, Freeman A, Mak J, et al
    Same day service: A genetic testing station model to improve germline genetic testing in patients with ovarian cancer.
    Gynecol Oncol. 2023;177:53-59.
    >> Share

  832. KIM JH, Park KN, Park EY, Jang MJ, et al
    Impact of warm saline irrigation, hyperthermic intraperitoneal chemotherapy on postoperative pain in primary ovarian cancer from the KOV-HIPEC-01 randomized trial.
    Gynecol Oncol. 2023;177:32-37.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016